



Quality indicators for colonoscopy

Colonoscopy is the cornerstone of colorectal cancer (CRC) prevention worldwide and in the United States.¹⁻⁴ In the United States, colonoscopy is commonly used for primary CRC screening and is the first and preferred colorectal imaging test in patients presenting with symptoms, with positive screening tests other than colonoscopy,¹⁻⁴ undergoing surveillance after resection of CRC or precancerous polyps,^{5,6} with a strong family history of CRC or advanced precancerous lesions,¹ and undergoing dysplasia surveillance in ulcerative colitis (UC) and Crohn's colitis.⁷

Evidence indicates colonoscopy reduces the incidence of CRC and prevents CRC mortality⁸⁻²³ (Table 1). Reduction in incidence and mortality of CRC with colonoscopy is greater in the left-sided colon than the right-sided colon.²⁴ In the first randomized controlled trial comparing colonoscopy with no screening, patients who complied with and underwent colonoscopy (per-protocol analysis) had a 31% reduction in CRC incidence and a 50% reduction in CRC mortality.²⁵ Several factors, including earlier than planned reporting of trial results, absence of stage shift in CRCs detected in the colonoscopy arm (suggesting symptomatic patients were enrolled in the colonoscopy arm), and lower than expected cecal intubation and adenoma detection, indicate the study may have underestimated the benefits of colonoscopy.²⁵

The impact of colonoscopy on CRC and other outcomes (eg, polyp detection, assignment of screening, and surveillance intervals) is highly operator-dependent. Detection of precancerous colorectal lesions is highly variable²⁶⁻²⁸ and is associated with the risk of developing postcolonoscopy CRC (PCCRC).^{21,22} In response to evidence of inconsistent performance, professional gastroenterology and endoscopy societies began an organized movement 2 decades ago to improve the quality of technical performance and reduce the operator-dependence of colonoscopy.²⁹ This document represents the latest update of recommendations from the American Society for Gastrointestinal Endoscopy (ASGE)/American College

of Gastroenterology (ACG) Quality Task Force. Previous recommendations from this task force were published in 2006³⁰ and 2015.³¹ This update reflects new evidence published since 2015.

High-quality colonoscopy includes adequate bowel preparation, safe colonoscope insertion to the proximal extent of the colon, detailed examination with identification of all precancerous lesions, and complete and curative resection of these lesions. The process is completed by thorough and accurate documentation of findings and assignment of any appropriate screening or surveillance follow-up at cost-effective intervals based on recommendations from the U.S. Multi-Society Task Force (MSTF) on CRC.³² High-quality performance in 1 aspect of colonoscopy does not ensure adequate performance in others. For example, colonoscopists may be effective at detection but not resection of precancerous lesions or vice versa.³³ Understanding deficiencies in performance is generally gained only through quality measurement. Given the impact of inadequate performance on critical outcomes including cancer development, failure to measure performance is unacceptable.

This document presents many quality indicators related to the technical performance of colonoscopy. Practicing colonoscopists are encouraged to make quality measurements related to all indicators, but this may not be feasible from a time, staffing, or cost perspective. Therefore, the document recommends priority quality indicators (Table 2). These indicators were chosen based on clinical relevance, evidence of variable performance, and feasibility of measurement. Measurement of priority indicators is considered essential.

METHODOLOGY

The first version of this document was published by the ASGE/ACG Task Force on Quality in Endoscopy in 2006³⁰ and was revised in 2015.³¹ This current revision integrates new data relevant to existing quality indicators and introduces new indicators based on interval progress in the field. This document focuses on quality indicators unique to colonoscopy (Table 3). The indicators common to all GI endoscopic procedures are presented in detail in a separate article³⁴ and are, for completeness, also listed in Table 4. Indicators common to all GI endoscopic procedures are not addressed in this document, except in some instances where discussion specific to colonoscopy is required.

As in the preceding versions, we prioritized indicators that have wide-ranging clinical implications, are associated with variation in practice and outcomes, and have been

This article is being published jointly in *Gastrointestinal Endoscopy* and *The American Journal of Gastroenterology*. The article is identical except for minor stylistic and spelling differences in keeping with each journal's style. Citations from either journal can be used when citing this article.

Copyright © 2024 by the American Society for Gastrointestinal Endoscopy and the American College of Gastroenterology
0016-5107/\$36.00
<https://doi.org/10.1016/j.gie.2024.04.2905>

TABLE 1. Evidence indicates that colonoscopy is able to reduce the incidence of CRC and prevent CRC mortality⁸⁻²³

• Incidence of CRC is lower in patients undergoing screening fecal blood tests.
• Incidence of right-sided colon cancer is lower in patients undergoing screening flexible sigmoidoscopy with liberal rules for performing colonoscopy based on flexible sigmoidoscopy findings.
• CRC incidence and mortality are reduced in adenoma cohorts compared with reference populations.
• CRC incidence in screening cohorts is reduced compared with reference populations.
• Case-control studies in screening and nonscreening populations show reduction in incidence and mortality.
• Case-control studies show reductions in right-sided CRC incidence and mortality in screening and nonscreening populations.
• Evidence from U.S. population trends.
• Studies show variable prevention between endoscopists with different detection skills.

CRC, Colorectal cancer.

TABLE 2. Priority quality indicators for colonoscopy

• Adenoma detection rate
• Sessile serrated lesion detection rate*
• Rate of using recommended screening and surveillance intervals
• Bowel preparation adequacy rate*
• Cecal intubation rate†

*Designates a new priority indicator.

†Should be measured for all colonoscopists but can be measured intermittently or not at all if consistent high-level performance has been demonstrated.

validated in clinical studies. When supportive data were absent, indicators of clinical importance were chosen by expert consensus. We have made substantial progress in measuring performance; however, feasibility and efficiency challenges remain. The task force included a limited number of highly relevant but not yet easily measurable indicators.

As stated before,^{30,31} quality indicators are divided into 3 time periods: preprocedure, intraprocedure, and postprocedure. Each quality indicator is classified as an outcome or process measure. Outcome measures are impactful in improving quality of care but can be difficult to measure in clinical practice. Outcome measures often require large amounts of data and/or long-term follow-up, and their measurement may be confounded by other factors. In such cases, process indicators are provided as surrogate measures of high-quality endoscopic practice. The relative value of a process indicator hinges on the evidence supporting its association with a clinically relevant outcome, and such process measures are emphasized. The measures in this document pertain to endoscopic care. The quality of care is influenced by additional factors, including those related to endoscopy centers. These structural measures are covered in a separate article dedicated to unit-level quality.³⁵

For this update, the task force critically appraised existing quality indicators based on several factors, including ongoing relevance and strength of evidence. Additionally, new quality indicators were proposed and, if appropriate, were adopted by consensus based on similar considerations. For each indicator, relevant articles were identified by the authors through a systematic search of PubMed

(U.S. National Library of Medicine, National Institutes of Health) from January 2014 (the date of the last update of this document) through December 2022. The search strategies for each indicator included a combination of subject headings (MeSH in PubMed) and pertinent keywords. English language restrictions were applied. To identify additional articles, the authors reviewed PubMed's "similar articles" and manually searched reference lists of relevant articles. Searches were facilitated by health science librarians with expertise in systematic review. Based on this revised literature review, the strength of recommendation for each indicator was evaluated according to a previously used framework (Table 5). Within this framework, the strength of each quality indicator was divided across a spectrum from "1A," denoting a strong quality indicator that can be applied to most clinical settings, to "3," denoting a weak quality indicator because of a lack of evidence requiring expert opinion. The strength of recommendation grade for each indicator was established with consensus of the authors.

The process and outcome measures included in this document are attached to a performance target, and therefore each measure is considered a quality indicator. The task force selected performance targets based on published benchmarking data, informed by literature review. In the absence of available data, when expert consensus considered the failure to perform a given quality indicator a "never event," such as failure to monitor vital signs during sedation, the performance target was expressed as >98%, because only in exceptional circumstances would the quality indicator not be fulfilled.

Quality indicators are intended to serve as a framework for quality improvement efforts. The included quality indicators and associated performance targets do not necessarily reflect the standard of care, credentialing requirements, or training standards, and it is a misuse to apply any of the quality indicators in this document as such.

PRIORITY INDICATORS

The 2006 and 2015 ASGE/ACG quality documents proposed many indicators for quality measurement in the

TABLE 3. Quality indicators for colonoscopy

Quality indicator	Strength of recommendation	Measure type	Performance target (% [unless otherwise indicated])
<i>General colonoscopy quality indicators</i>			
<i>Preprocedure</i>			
1. Frequency with which colonoscopy is performed for an appropriate indication and the indication is documented.	1C+	Process	≥95
2. Rate of bowel preparation adequacy* Percentage of patients undergoing colonoscopy with adequate bowel preparation, preferably defined as Boston Bowel Preparation Scale score ≥2 in each of 3 colon segments or by description of the preparation as excellent, good, or adequate. The recommended screening or surveillance interval should be consistent with U.S. Multi-Society Task Force recommendations.	1C	Process	≥90
<i>Intraprocedure</i>			
3. Cecal intubation rate* Percentage of patients undergoing colonoscopy with intact colons who have full intubation of the cecum with photo documentation of cecal landmarks.	1C	Process	≥95
<i>Detection indicators for colonoscopy</i>			
4. Adenoma detection rate* Percentage of patients aged ≥45 y undergoing colonoscopy for screening, surveillance, or diagnostic indications other than positive noncolonoscopy screening tests (eg, fecal tests or CT colonography) who have ≥1 conventional adenomas detected and verified by pathology. Patients with positive noncolonoscopy screening tests, genetic cancer syndromes (eg, polyposis), IBD, or undergoing colonoscopy for therapy of known neoplasms are excluded from the calculation.	1C+	Outcome	≥35
5. Percentage of patients with positive fecal screening tests (fecal blood or mt-sDNA) with ≥1 conventional adenomas resected and documented by pathology.	1C	Outcome	≥50
6. Number of conventional adenomas detected per colonoscopy in patients aged ≥45 y with indications of screening, surveillance, or diagnosis of symptoms. Patients with positive noncolonoscopy screening tests, genetic cancer syndromes (eg, polyposis), IBD, or undergoing colonoscopy for therapy of known neoplasms are excluded from the calculation.	2C	Outcome	≥6
7. Sessile serrated lesion detection rate* Percentage of patients aged ≥45 y undergoing screening, surveillance, or diagnostic colonoscopy for symptoms with ≥1 sessile serrated lesions removed and documented by pathology. Patients with positive noncolonoscopy screening tests, genetic cancer syndromes (eg, polyposis), IBD, or undergoing colonoscopy for therapy of known neoplasms are excluded from the calculation.	2C	Outcome	≥6
8. Average withdrawal time in normal colonoscopies without biopsy sampling or polypectomies in persons aged ≥45 y undergoing screening, surveillance, or diagnostic colonoscopy. Patients with positive noncolonoscopy screening tests, genetic cancer syndromes (eg, polyposis), IBD, or undergoing colonoscopy for therapy of known neoplasms are excluded from the calculation.	2A	Process	≥8 min
<i>Resection indicators</i>			
9. Percentage of polyp resections for which the report documents the lesion size, shape, location, and method of resection.	3	Process	≥98
10. Percentage of 4- to 9-mm lesions that are resected using a cold snare.	1A	Process	≥90
<i>Postprocedure</i>			
11. Use of appropriate screening and surveillance intervals* Frequency with which colonoscopies follow recommended postpolypectomy and post-cancer resection surveillance intervals and frequency of 10-y intervals between screening colonoscopies in average risk patients who have negative examination results and adequate bowel cleansing.	1C	Process	≥90
12. Proportion of serious adverse events (perforation, postpolypectomy bleeding, and mortality) associated with colonoscopy that are tracked, documented, and reviewed by a quality improvement committee to assess for system and clinical areas of improvement.	1C	Process	≥95

(continued on the next page)

TABLE 3. Continued

Quality indicator	Strength of recommendation	Measure type	Performance target (% [unless otherwise indicated])
<i>Quality indicators for colonoscopy in IBD</i>			
<i>IBD intraprocedure colonoscopy indicators</i>			
13. Percentage of colonoscopies performed for the indication of ulcerative colitis in which a formal assessment of disease extent and activity (Mayo Endoscopic Score, Modified Mayo Endoscopic Score, Ulcerative Colitis Endoscopic Index of Severity, or Ulcerative Colitis Colonoscopic Index of Severity) is recorded.	3	Process	≥90
14. Percentage of colonoscopies performed for the indication of Crohn's disease in which a formal disease activity score (Crohn's Disease Endoscopic Index of Severity, or Simple Endoscopic Activity Score in Crohn's Disease, or Rutgeerts score) is reported.	3	Process	≥90
<i>IBD postcolonoscopy quality indicators</i>			
15. Frequency of appropriate recommendation for a follow-up surveillance colonoscopy interval for ulcerative colitis/indeterminate colitis patients undergoing dysplasia screening without dysplasia detected.	3	Process	≥90

IBD, Inflammatory bowel disease; *mt-sDNA*, multi-target stool DNA.

*Indicates priority indicator.

technical performance of colonoscopy.^{30,31} Quality measurement is relatively new and requires resources. The 2015 document proposed priority indicators that every endoscopy unit should endeavor to measure.

This current revision also proposes priority indicators (Table 2). Priority indicators reflect the strength with which they are linked to important colonoscopy outcomes, such as prevention of cancer and cancer death, the feasibility of measurement in clinical practice, evidence for variability in performance, and consensus regarding the significance of the indicator as a continuing or emerging element of high-quality technical performance of colonoscopy. The rationale for selection of priority indicators in this document (Table 2) is largely presented in the discussion of individual indicators below. We recommend that quality improvement efforts initially focus on high-priority indicators and then progress to other indicators once it is ascertained that endoscopists are performing above recommended thresholds, either at baseline or after corrective interventions.

The cecal intubation rate (CIR) remains a quality indicator for colonoscopy in this update. However, although CIR was a priority indicator in 2015,³¹ its status as a priority indicator has been changed in this update (Table 2). High CIRs are associated with prevention of CRC,³⁶ and failed intubation leads to costs and inconvenience associated with supplementary imaging and repeat attempts at colonoscopy. Thus, we continue to recommend measurement of CIRs. However, substantial evidence indicates that most gastroenterologists achieve CIRs above recommended thresholds and maintain them.^{37,38} Therefore, a sustained measurement of CIRs may not be an effective use of resources in units where there is no evidence of inadequate performance.

New priority indicators are noted by an asterisk in Table 2. One of these is adequacy of bowel preparation,

which is fundamental to cost-effective colonoscopy. The second is the sessile serrated lesion detection rate (SSLDR), which is selected based on evidence it will contribute to cancer prevention (see Indicator 7 below).

GENERAL COLONOSCOPY INDICATORS

Preprocedure indicators

Appropriate indications for colonoscopy.

1. *Frequency with which colonoscopy is performed for an appropriate indication and the indication is documented.*

Strength of recommendation: 1C+

Performance target: ≥95%

Measure type: process

Appropriate indications for colonoscopy are listed in Table 6. Each procedure report should include an accepted indication or an explanation if the indication is considered nonstandard. Dates and findings from prior colonoscopies (eg, cancer, advanced lesions, or nonadvanced lesions) that drive the current colonoscopy should be documented with the indication.

When colonoscopy is used for appropriate indications, there is a higher yield of clinically relevant diagnoses.³⁹⁻⁴² List for accepted indications can be used to screen colonoscopy referrals for appropriateness.⁴³⁻⁴⁶

Rate of bowel preparation adequacy (priority indicator).

2. *Percentage of patients undergoing colonoscopy with adequate bowel preparation, preferably defined as Boston Bowel Preparation Scale score ≥2 in each of 3 colon segments or by description of the preparation as excellent, good, or adequate. The recommended screening or surveillance interval should be consistent with U.S. MSTF recommendations.*

TABLE 4. Quality indicators common to all endoscopic procedures with associated performance targets

Quality indicator	Strength of recommendation	Measure type	Performance target (%)
<i>Preprocedure</i>			
1. Frequency with which endoscopy is performed for an indication that is included in a published standard list of appropriate indications and the indication is documented (priority indicator).	1C+	Process	>95
2. Frequency with which informed consent is obtained and documented.	3	Process	>98
3. Frequency with which preprocedure history and directed physical examination are performed and documented.	3	Process	>98
4. Frequency with which a sedation plan that includes risk for sedation-related adverse events is documented before sedation is initiated.	3	Process	>98
5. Frequency with which prophylactic antibiotics are administered for appropriate indications (priority indicator).	Varies	Process	>98
6. Frequency with which management of antithrombotic therapy is formulated and documented before the procedure (priority indicator).	3	Process	>95
7. Frequency with which a team pause is performed and documented.	3	Process	>98
8. Frequency with which endoscopy is performed or supervised by an individual who is fully trained and appropriately credentialed to perform that particular procedure.	3	Process	>98
<i>Intraprocedure</i>			
9. Frequency with which photo documentation is performed.	3	Process	>90
10. Frequency with which patient monitoring during sedation is performed and documented.	3	Process	>98
11. Frequency with which procedure interruption and premature termination because of sedation-related issues is documented.	3	Process	>98
12. Frequency with which endoscopic specimen verification is performed and documented.	3	Process	>98
<i>Postprocedure</i>			
13. Frequency with which discharge from the endoscopy unit according to predetermined discharge criteria is documented.	3	Process	>98
14. Frequency with which patient instructions are provided.	3	Process	>98
15. Frequency with which endoscopic findings, pathology results, and follow-up recommendations are communicated to the patient and appropriate providers.	3	Process	>98
16. Frequency with which a complete procedure report is created.	3	Process	>98
17. Frequency with which adverse events are documented (priority indicator).	3	Process	>98
18. Frequency with which adverse events occur.	Varies	Outcome	N/A
19. Frequency with which patient satisfaction data are collected.	N/A	Outcome	N/A

N/A, Not applicable.

Strength of recommendation: 1C

Performance target: $\geq 90\%$

Measure type: process

The ASGE/ACG Task Force on Quality Indicators for Colonoscopy relies heavily on the bowel preparation recommendations of the U.S. MSTF.⁴⁷ When bowel preparation is adequate, the subsequent recommended interval for repeat screening or surveillance colonoscopy should be consistent with the U.S. MSTF recommendations^{6,47} unless a documented indication exists for earlier colonoscopy (eg, an inherited genetic disorder, strong family history, or a disease process such as chronic inflammatory bowel disease [IBD]).

As per the U.S. MSTF recommendations, patients with inadequate bowel preparation should have a repeat study within 1 year.⁴⁷ The U.S. MSTF recommended in 2014 that at least 85% of outpatient colonoscopies should be

accompanied by an adequate bowel preparation.⁴⁷ The European Society of Gastrointestinal Endoscopy recommended a 90% target.⁴⁸ The U.S. MSTF recommendations are currently under revision, and based on continued evidence of high rates of adequate preparation in clinical trials,⁴⁹ the ASGE/ACG Task Force recommends the 90% threshold. Inadequate bowel preparation substantially increases the cost of colonoscopy delivery⁵⁰ and creates risk and inconvenience for patients, thus warranting a ranking as a priority indicator.

Like the U.S. MSTF, we recommend that the colonoscopy report in the case of adequate preparation should include descriptors of bowel preparation as “adequate,” “excellent,” or “good” or record a Boston Bowel Preparation Scale score of ≥ 2 in all 3 colon segments.^{51,52} Because it uses scores and explicit descriptions of what the scores mean, the Boston Bowel Preparation Scale is preferred. Further, the Boston

TABLE 5. Strength of recommendations

Strength of recommendation	Clarity of benefit	Methodologic strength supporting evidence	Implications
1A	Clear	Randomized trials without important limitations	Strong recommendation; can be applied to most clinical settings
1B	Clear	Randomized trials with important limitations (inconsistent results, nonfatal methodologic flaws)	Strong recommendation; likely to apply to most practice settings
1C+	Clear	Overwhelming evidence from observational studies	Strong recommendation; can apply to most practice settings in most situations
1C	Clear	Observational studies	Intermediate-strength recommendation; may change when stronger evidence is available
2A	Unclear	Randomized trials without important limitations	Intermediate-strength recommendation; best action may differ depending on circumstances or patients' or societal values
2B	Unclear	Randomized trials with important limitations (inconsistent results, nonfatal methodologic flaws)	Weak recommendation; alternative approaches may be better under some circumstances
2C	Unclear	Observational studies	Very weak recommendation; alternative approaches are likely to be better under some circumstances
3	Unclear	Expert opinion only	Weak recommendation; likely to change as data becomes available

Adapted from Guyatt G, Sinclair J, Cook D, et al. Moving from evidence to action. Grading recommendations—a qualitative approach. In: Guyatt G, Rennie D, editors. Users' guides to the medical literature. Chicago, IL: AMA Press; 2002. p. 599-608.

TABLE 6. Appropriate indications for colonoscopy

1. Evaluation of unexplained GI bleeding <ol style="list-style-type: none"> Hematochezia Melena with upper GI cause excluded Presence of fecal occult blood
2. Unexplained iron deficiency anemia
3. Screening for colorectal neoplasia at recommended intervals in average-risk persons or persons with significant high-risk family histories
4. Surveillance in Lynch syndrome
5. Surveillance in patients with polyposis syndromes
6. Surveillance at recommended intervals for prior colorectal cancer or precancerous lesions
7. Surveillance at recommended intervals of cancer risk in inflammatory bowel disease
8. Assessment of disease activity in inflammatory bowel disease for purpose of assessing treatment response
9. Clinically significant diarrhea of unexplained origin
10. Evaluation of abnormal imaging of the colorectum that suggests cancer, precancerous lesions, or clinically important bowel-wall abnormalities
11. Intraoperative identification of a lesion not apparent or found at surgery
12. Treatment of bleeding lesions such as vascular malformations, ulceration, neoplasia, and postpolypectomy ulcers
13. Foreign body removal
14. Excision of polyp or early-stage colorectal cancer
15. Decompression of acute nontoxic megacolon or sigmoid volvulus
16. Treatment of stenosis
17. Palliative treatment of stenosing or bleeding neoplasm
18. Marking a neoplasm for localization
19. Positive fecal or blood-based colorectal cancer screening test

Bowel Preparation Scale is specifically designed for use after completion of intraprocedural bowel cleaning, which is the most clinically relevant time point to assess cleansing quality. To count toward meeting the 90% compliance target, the recommended follow-up interval must be consistent with U.S. MSTF postpolypectomy³² or postcancer resection⁵³ surveillance recommendations.

Intraprocedure indicators

Cecal intubation rate (priority indicator).

3. Percentage of patients undergoing colonoscopy with intact colons who have full intubation of the cecum with photo documentation of cecal landmarks.

Strength of recommendation: 1C

Performance target: $\geq 95\%$

Measure type: process

A trained colonoscopist should achieve a high CIR with a very high level of safety. Cecal intubation is defined as passage of the colonoscope tip proximal to the ileocecal valve and fully into the cecal caput so that the appendiceal orifice can be identified and photographed and the medial wall of the cecum between the appendiceal orifice and ileocecal valve can be thoroughly examined.³¹ Low CIRs have been associated with higher PCCRC rates.³⁶

High CIRs should be achievable with extremely low rates of insertion-related perforation. Mechanical rupture of the colon can be prevented by reduction of loops and bends in the insertion tube and avoiding pushing against fixed resistance. Use of thinner, more-flexible instruments can reduce rupture risk when the colon is diseased from conditions such as severe diverticular disease, radiation injury, chronic dialysis, long-term corticosteroid use, or fixation because of pelvic surgery. Barotrauma perforations occur only in patients with severe sigmoid angulation and narrowing, primarily associated with severe diverticular disease. The risk of barotrauma should be anticipated in all patients with a complex sigmoid colon, and the colonoscopist should consider stopping gas insufflation and using water immersion until the sigmoid is traversed and the proximal colon decompressed.⁵⁴

CIRs above 95% for all indications are readily achievable by high percentages of independently practicing colonoscopists.^{37,55-58} All independently practicing colonoscopists should have CIRs measured until they are consistently above the recommended target. After this, continued CIR measurement is optional and can be performed intermittently or not at all in the case of a consistent track record of performance above recommended thresholds. Limited evidence of variable performance for many practicing gastroenterologists, evidence that high performance is sustained, and the obvious ceiling level of 100% justify reduction in measurement for high-level performers.

Adenoma detection rate (priority indicator).

4. *Percentage of patients aged ≥ 45 years undergoing colonoscopy for screening, surveillance, or diagnostic indications other than positive noncolonoscopy screening tests (eg, fecal tests or CT colonography) who have 1 or more conventional adenomas detected and verified by pathology. Patients with positive noncolonoscopy screening tests, genetic cancer syndromes (eg, polyposis), IBD, or undergoing colonoscopy for therapy of known neoplasms are excluded from the calculation.*

Strength of recommendation: 1C+

Performance target: $\geq 35\%$

Measure type: outcome

The adenoma detection rate (ADR) is the most clinically relevant and best validated quality indicator in colonoscopy. ADR was proposed in 2002²⁹ in response to evidence that adenoma detection and cancer prevention were variable in clinical practice and was defined as the percentage of patients aged ≥ 50 years undergoing colonoscopy for

indications other than IBD or polyposis syndromes who had ≥ 1 conventional adenoma resected and verified by pathology. The initial proposed threshold was 20% (25% in men and 15% in women) and was arbitrarily set at a level below the mean prevalence of adenomas detected at initial screening colonoscopy studies performed in average-risk individuals.⁵⁹⁻⁶² In 2006 the recommendation for ADR was changed to the fraction of patients aged ≥ 50 years having ≥ 1 conventional adenoma in a first-time screening colonoscopy.³⁰ This change acknowledged that the original target levels were derived from screening colonoscopy studies.⁵⁹⁻⁶² In 2010, a large screening colonoscopy study showed that hazard ratios for PCCRC were increased 10-fold when colonoscopy was performed by colonoscopists with ADRs $< 20\%$ compared with colonoscopy performed by colonoscopists with ADRs $> 20\%$.²¹ In 2015, the minimum acceptable thresholds were increased to 25% (30% in men and 20% in women)³¹ after a large study showed further gains in protection against PCCRC with ADRs above 20%.²² Since 2015, changes in screening guidelines and new evidence support additional modifications to the ADR.

First, an increase in early-onset CRC led to reducing the recommended age to start CRC screening to 45 years.^{2-4,63} To keep the ADR measurement consistent with the currently recommended age to begin screening, we now recommend that the ADR should be measured in persons aged ≥ 45 years rather than age 50 years. Because adenoma prevalence is related primarily to age, this change might warrant a downward adjustment in the minimum acceptable threshold. However, more-recent studies found adenoma prevalence in 45- to 49-year-olds to be only slightly lower than in 50- to 54-year-olds⁶⁴⁻⁷¹ (Table 7). Because mean ADRs have been steadily increasing over the past decade⁷² and the proportion of patients aged 45 to 49 years undergoing colonoscopy is still relatively small compared with persons aged ≥ 50 years (Table 6), we recommend no adjustment in the minimum acceptable threshold for the ADR is warranted for inclusion of 45- to 49-year-olds in the ADR measurement.

Second, several studies reported the incidence of adenomas at a second screening colonoscopy performed 10 years after an initial negative screening colonoscopy^{23,68,73-76} (Table 8). Adenoma incidence at 10 years is just slightly below that identified at an initial screening colonoscopy, despite patients being 10 years older. In light of this evidence, we recommend that second and subsequent screening colonoscopies can be included in the ADR calculation without adjustment for the minimum acceptable ADR threshold.

Third, as noted above, the original definition of ADR included surveillance (colonoscopy for prior neoplasia) and diagnostic examinations (colonoscopy for symptoms).²⁹ The recommendation to confine the ADR measurement to screening was made in 2006³⁰ because the 2002 targets had been based on screening studies. In this update, we recommend expanding the definition of a

TABLE 7. ADR in those aged 45 to 49 year vs 50 to 54 years

Reference	Years of colonoscopy performance	No. of examinations in patients aged 45-49 y	ADR in patients aged 45-49 y (%)	ADR in patients aged 50-54 y (%)	Examinations in patients aged 45-49 y (%)
Karsenti et al 2019 ⁶⁴	2016	515	21.2 (19% average-risk screen)	25.2	N/A
Butterly et al 2021 ⁶⁶	2004-2018	1869	17.5	22.1	4.6
Imperiale et al 2021 ⁶⁵ (multitarget stool DNA study)	2019*	816	31	N/A	N/A
Shaukat et al 2022 ⁶⁷	2015-2019	4841	28.4	31.1	3.1
Ladabaum et al 2022 ⁶⁸	2019-2021*	350	34.3	38.2	11.6
Liang et al 2022 ⁶⁹ (GIQuIC)	2010-2020	92,752	28.0	33.0	5.0
Bilal et al 2022 ⁷⁰ (GIQuIC)	2014-2020	47,213	28.6	31.8	1.6
Trivedi et al 2022 ⁷¹ (AMSURG → GIQuIC)	2014-2021	79,934	32	37.7	N/A

ADR, Adenoma detection rate; N/A, not available; GIQuIC, GI Quality Improvement Consortium, Ltd (Bethesda, Md, USA); AMSURG, AmSurg Corporation (Nashville Tenn, USA).
*All in the era after the 2018 American Cancer Society guidelines.

TABLE 8. Incidence of adenomas at a second screening colonoscopy performed 10 years after an initial negative screening colonoscopy

Reference	Years	ADR at the first screening (%)	ADR at the second screening (%)
Ponugoti et al 2017 ⁷⁵	2007-2015	N/A	38
Rex et al 2018 ⁷⁶	2010-2015	32	27
Ladabaum et al 2021 ²³	2017-2020	36	29
Ladabaum et al 2022 ⁶⁸	2019-2021	43	33

ADR, Adenoma detection rate; N/A, not available.

routine ADR to again include both surveillance and diagnostic examinations not performed for positive fecal tests. Given the potential for heterogeneity in adenoma prevalence based on colonoscopy indication, one logical concern is that broadening the ADR calculation to include all surveillance and diagnostic colonoscopies might introduce bias based on patient mix. However, in the aggregate, any bias introduced by heterogeneity is expected to be modest. In general, ADRs for postpolypectomy surveillance colonoscopies are approximately 7% to 12% higher than ADRs for screening colonoscopies^{22,67,77-84} (Table 9), whereas ADRs for diagnostic colonoscopies that do not include significant numbers of positive fecal tests are lower than those for screening colonoscopy. Thus, a combined ADR including screening, surveillance, and nonfecal test diagnostic colonoscopies is often similar to a screening ADR.⁸² A modeling study found that a combined ADR stratified endoscopists into high and low detectors as accurately as the screening ADR over a range of indication distributions.⁸²

Notably excluded from the routine ADR calculation are colonoscopies performed for positive fecal testing. Although the ADR is predictive of PCCRC in patients with positive fecal blood tests,⁸⁵ the ADR consistently runs at least an absolute 15% higher in patients with positive fecal tests.⁸⁶⁻⁹⁰ Therefore, positive fecal tests are distinct from other diagnostic indications. The use of fecal testing varies regionally and across health practices in the United States, and therefore the fraction of colonoscopies performed for positive

fecal blood tests is expected to vary substantially across practices. In settings where the proportion of examinations for a positive fecal immunochemical test (FIT) is substantial (as in organized screening programs) and FIT-positive evaluations are distributed similarly across endoscopists, FIT-positive examinations can be included in the general calculation of the ADR for purposes of internal comparisons of endoscopists.⁹¹ However, inclusion of positive fecal tests in the general ADR calculation makes comparisons of ADRs across U.S. institutions and with international results challenging. Therefore, we recommend that ADRs in FIT-positive patients should usually be measured separately (see Indicator 5 below). Further, if detection performance is measured in inpatients, it is reasonable to exclude patients from ADRs and all other detection measures when the indication would not be reasonably expected to include polyp resection (eg, colonoscopy for acute major lower GI hemorrhage or colonic decompression).

Finally, multiple reports indicate ADRs have risen steadily over the past decade.^{70,92,93} In a large registry, mean screening ADRs in U.S. gastroenterology practices had risen to 38% by 2018.⁷⁰ In a 2014 study, the risk of PCCRC and fatal PCCRC were shown to decrease by 3% and 5%, respectively, for each 1% increase in the ADR.²² In a subsequent study, this relationship between ADR and PCCRC was shown to hold during the interval from 2010 to 2018, when ADRs were generally higher, and the relationship extended to ADRs above 40%.⁹² Further, the relationship holds for

TABLE 9. Association of ADR and colonoscopy indication

Reference	Years of colonoscopy	All screening ADR (%)	Surveillance ADR (%)	Symptomatic or diagnostic ADR (%)	Global ADR (%)
Anderson et al 2013 ⁷⁷	2009-2011	25	37	N/A	29
Marcondes et al 2015 ⁷⁸	2009-2013	37	59	15-34	39
Boroff et al 2017 ⁷⁹	2010-2012	33	55	13-33	37
Rex and Ponugoti 2017 ⁸⁰	2010-2015	42	54	29	45
Brand et al 2017 ⁸¹	2013-2015	33-36	45-47	N/A	36-40
Kaltenbach et al 2021 ⁸²	2015	49	56	38	50
Kajzrlíkova et al 2021 ⁸⁴	2013-2017	46	48	36	43
Ladabaum et al 2021 ²³	2017-2020	36	44	17	N/A
Desai et al 2023 ⁸³	2017-2021	50	64	N/A	55-59
Shaukat et al 2022 ⁶⁷	2021	38-41	52-59	N/A	44-48

ADR, Adenoma detection rate; N/A, Not available.

colonoscopy performed for nonscreening indications.^{91,92} Improvements in ADRs in U.S. gastroenterology practices likely reflect the emphasis on quality measurement over the past 2 decades plus the widespread availability of high-definition colonoscopes.

Given the various considerations outlined above, we recommend that ADR calculations include screening, surveillance, and diagnostic colonoscopy but exclude indications of a positive noncolonoscopy screening test (eg, fecal blood test, multitarget stool DNA [mt-sDNA], CT colonography) and therapeutic procedures for resection or treatment of known neoplasia, genetic cancer syndromes (eg, polyposis), and IBD. Specific recommendations for ADRs in patients with positive fecal screening tests are in the next section.

Considering that ADRs have risen progressively in screening populations⁷² and that inclusion of surveillance procedures may raise ADRs by a significant extent for some colonoscopists, we now recommend a minimum threshold of 35% for the ADR (40% in men and 30% in women). We acknowledge that the actual level of ADR chosen as the minimum acceptable threshold (and therefore the fraction of endoscopists who are below the chosen threshold) carries an arbitrary element, but the considerations outlined above support this recommendation.

Colonoscopists with ADRs below 35% are recommended to undertake remedial measures to improve and to achieve acceptable performance. Because there is evidence that PCCRC risk continues to fall as ADRs move above 35%, we also recommend that all colonoscopists strive to achieve ADRs well above the minimum recommended threshold of 35%, and indeed ADRs can rise well above 40%.^{70,92-96}

Including more colonoscopies in the ADR measurement has potential advantages and disadvantages. Expanding the included indications results in a larger sample size, allowing benchmarking of a higher proportion of the practitioner's colonoscopies. With a higher number of included colonoscopies, the confidence interval is narrower and perfor-

mance conclusions more accurate, which is particularly useful for low-volume endoscopists.⁹⁷ The evidence that ADR predicts the risk of PCCRC after nonscreening examinations^{22,91,92} and also in patients with positive fecal blood tests⁸⁵ supports measurement of the performance across a wider range of colonoscopy indications. Adding more examinations to the ADR measurement, however, requires more resources to review and record pathology results, particularly if the process is performed manually. Automatic data extraction eliminates this issue but is frequently not available.

For all measures related to lesion detection, we recommend (if feasible and practical in the context of local measurement programs) excluding examinations where the procedure is aborted during insertion because of inadequate preparation or the examination is complete to the cecum but is rescheduled within 1 year. In both cases, we recommend photo documentation of poor preparation to support the need for repeat examination. We also recommend excluding procedures that are incomplete to the cecum or an ileocolic anastomosis because of abnormal colonic anatomy (eg, marked redundancy or severe sigmoid angulation and narrowing).

ADR in patients with positive fecal screening tests.

5. *Percentage of patients with positive fecal screening tests (fecal blood or mt-sDNA) with 1 or more conventional adenomas resected and documented by pathology.*

Strength of recommendation: 1C

Performance target: $\geq 50\%$

Measure type: outcome

We continue to recommend exclusion of colonoscopies for positive fecal screening tests from the routine ADR calculation as discussed above. This exclusion is partly because the fraction of colonoscopies performed for positive fecal screening tests varies widely. The fraction is often low in U.S. centers where opportunistic screening is performed

and can be substantially higher in healthcare systems with organized FIT-based screening.⁹⁸ Thus, and because the ADR is higher in these patients, exclusion of positive fecal screening tests from routine ADR calculations allows better comparison of the ADR across healthcare systems.

In some instances, the number of colonoscopies performed for positive fecal screening tests is sufficiently high to warrant measurement of the ADR within this patient group. ADRs in the FIT-positive population do predict PCCRC risk.⁸⁵ The prevalence of adenomas in FIT-positive patients is well documented and can reach as high as 70%.⁹⁹ The ADR is higher when the cut-off level of hemoglobin per gram of feces for a positive test is higher.⁹⁹ Like the primary screening population, adenoma prevalence in men with a positive FIT is typically 10% to 15% higher than women.⁹⁹ In the United States, a cut-off of 20 µg hemoglobin per gram of feces is often used in FIT assays.⁹⁹

Based on the available evidence, we recommend an ADR of 50% (55% in men and 45% in women) in FIT-positive populations where assays with a cut-off of 20 µg hemoglobin per gram of feces are used. There is less evidence regarding the expected ADR in patients with a positive mt-sDNA test.^{87,100-103} Although evidence is limited, we currently recommend the same threshold for ADR in mt-sDNA-positive patients as for FIT-positive patients.

Adenomas per colonoscopy.

6. *Number of conventional adenomas detected per colonoscopy in patients aged ≥45 years with indications of screening, surveillance, or diagnosis of symptoms. Patients with positive noncolonoscopy screening tests, genetic cancer syndromes (eg, polyposis), IBD, or undergoing colonoscopy for therapy of known neoplasms are excluded from the calculation.*

Strength of recommendation: 2C

Performance target: ≥.6

Measure type: outcome

The ADR has strengths and weaknesses as a quality indicator. Strengths are its use as a total colon measure in which the differentiation of conventional adenomas from lesions in the serrated category by pathologists is generally straightforward with limited interobserver variation¹⁰⁴ as well as it being validated as a predictor of PCCRC.¹⁰⁵ A principal weakness of the ADR is that it does not reward detection of additional adenomas after the first adenoma has been identified and resected, and many patients have multiple adenomas. This shortcoming has led to measures such as adenomas per colonoscopy (APC), which rewards detection and resection of each adenoma. Like the ADR, higher APC has been associated with a lower risk of PCCRC.¹⁰⁶

In general, the correlation between ADR and APC is high.¹⁰⁷⁻¹¹⁰ Despite this correlation, instances have been documented in which an adequate ADR has been associated with low APC in important fractions of endoscopists.^{109,111} For example, in 1 study, 47.6% of endoscopists in the lowest quartile of APC performance had ADRs ≥25%, whereas none of the endoscopists in the high-

est quartile of APC performance had ADRs <25%.¹⁰⁹ Based on these features, we recommend that APC can be considered as an alternative to ADR in practices where ADRs are generally high and endoscopists are seeking additional information that can identify and discriminate suboptimal performance. In this regard, a minimum threshold for APC of .6 is recommended,^{105,107-110,112,113} but levels above 1.2 are achievable.⁹⁵ APC may not provide additional important information when the ADR is low.

The major downside of APC is the potential for a perceived incentive to separate adenomas into separate preservative bottles for pathologic examination. Such a practice increases costs and is not recommended to improve the accuracy of tabulating APC. An alternative approach is to record the number of individual adenomas detected as well as photographs in the procedure report. The photographs serve to support the total number of adenomas identified in the colonoscopy procedure. This approach could be used as an alternative way of counting ADR or APC with a “resect and discard” strategy. In the absence of a resect and discard practice, however, photography can still be used to document the number of adenomas identified so that submitting adenomas in separate bottles is minimized.¹¹⁴

Sessile serrated lesion detection rate (priority indicator).

7. *Percentage of patients ages ≥45 years undergoing screening, surveillance, or diagnostic colonoscopy for symptoms with 1 or more sessile serrated lesions (SSLs) removed and documented by pathology. Patients with positive noncolonoscopy screening tests, genetic cancer syndromes (eg, polyposis), IBD, or undergoing colonoscopy for therapy of known neoplasms are excluded from the calculation.*

Strength of recommendation: 2C

Performance target: ≥6%

Measure type: outcome

The ASGE/ACG Quality Task Force on Colonoscopy Committee considered carefully and at length whether to add a detection target directed toward serrated lesions. A survey found that many U.S. endoscopists are still not measuring ADRs.¹¹⁵ Adding a separate indicator for detection of serrated lesions creates an additional measurement and resource burden for endoscopists and endoscopy units. Further, unique challenges are associated with the implementation of any serrated indicators that are not relevant to the ADR. First, substantial interobserver variation occurs among pathologists in the diagnosis of SSLs versus hyperplastic polyps.¹¹⁶⁻¹¹⁹ This is not an issue in the pathologic diagnosis of conventional adenomas.³¹ Second, a serrated indicator should ideally disincentivize the identification and resection of diminutive distal colon hyperplastic polyps, which are generally considered not to be precancerous.¹²⁰ However, an indicator that relies on endoscopist localization during colonoscopy could be subject to bias and gaming in prospective use.¹⁰⁵ Third, some measures of serrated

TABLE 10. Leading candidates for serrated lesion detection indicator

Rate	Benchmark (%)	Easy to calculate?	Measures endoscopist detection	Validating data
Clinically significant serrated detection rate	9	Requires path, size, and location	Some path influence	9% associated with lowest risk for PCCRC
Proximal serrated polyp detection rate	17	Location only	Least path dependent	17.0% associated with lowest risk for PCCRC
Sessile serrated lesion detection rate	6	Path only	Most influenced by path	6.0% associated with lowest risk for PCCRC

PCCRC, Postcolonoscopy colorectal cancer. Clinically significant serrated detection rate: Any serrated lesion (sessile serrated lesion, hyperplastic polyp, or traditional serrated adenoma) ≥ 10 mm or any serrated lesion >5 mm proximal to the sigmoid colon; proximal serrated polyp detection rate: fraction of colonoscopies with ≥ 1 serrated polyps (sessile serrated lesion, hyperplastic polyp, or traditional serrated adenoma) proximal to the splenic flexure; sessile serrated lesion detection rate: fraction of colonoscopies with ≥ 1 sessile serrated lesions.

detection have used polyp size.¹²¹ These measurements would be subject to substantial endoscopist bias and gaming in prospective use. Despite these cautionary notes, 3 recent studies found that ADR is insufficient as a sole detection indicator predicting PCCRC.¹²¹⁻¹²³ In 2 trials, ADR above 25% and low serrated lesion detection were found in 13% to 14% of endoscopists,^{122,123} whereas another 37% to 45% of endoscopists had ADRs below 25% and low serrated detection. In both studies, the correlation between ADR and serrated detection was moderate.^{122,123}

Although a variety of serrated detection indicators has been proposed,¹⁰⁵ the committee considered 3 (clinically significant serrated polyp, proximal serrated polyp, and SSLDR) because of their association with PCCRC in recent studies,^{121,122} and we recommend the SSLDR as the quality indicator of choice because it directly measures the precancerous serrated lesion of greatest interest and is not subject to endoscopist bias (Table 10).

We acknowledge that the SSLDR is subject to measurement and accuracy errors related to pathologist interobserver variation in differentiation of SSLs from hyperplastic polyps.¹¹⁶⁻¹¹⁹ Thus, the SSLDR may reflect pathologist performance and bias rather than endoscopist performance in some instances.¹¹⁷ This is a potentially serious flaw in endoscopy detection measures.¹⁰⁵ However, evidence shows that SSL detection is increasing rapidly with time¹²⁴ and that part of this increase reflects improved awareness and education among community pathologists of identification of SSLs. Further, introducing the SSLDR as a detection target should incentivize endoscopists to work with their pathologists to improve pathologic identification of SSLs.¹²⁵ Admittedly, any serrated detection indicator carries inherent flaws for prospective use.¹⁰⁵

To set the target threshold for a minimum SSLDR, we examined prevalence data on SSLs and the association of SSL detection with PCCRC. A systematic review and meta-analysis found a pooled SSL prevalence of 2.5%.¹²⁶ The reported prevalence of SSLs varies between countries, and the pooled prevalence in the United States was found to be 4.6%.¹²⁷ However, evidence of increasing SSL prevalence over time is clear,¹²⁴ with both endoscopist and pathology factors contributing to the increase. A registry

study from the United States involving more than 5.1 million colonoscopies and 3934 endoscopists found that the prevalence of 4.57% in 2014 increased to 7.14% in 2017.¹²⁴ Thus, the prevalence of SSLs as determined by colonoscopic detection is steadily rising.

Data suggest SSLDRs may not correlate closely with ADRs and that SSLDRs provide predictive data independent from ADRs, making it a worthy stand-alone quality indicator. A recent study from the Netherlands performed in FIT-positive patients showed that the proximal serrated polyp detection rate (PSPDR) and the SSLDR had similar associations with prevention of PCCRC.¹²² In a study from Austria, the magnitude of PCCRC mortality reduction was similar for increases in PSPDRs and SSLDRs, but the effect on mortality reduction did not reach significance for SSLDRs, probably because SSLs are less prevalent than proximal serrated polyps.¹²³ A greater prevalence is an advantage for PSPDRs as a detection measure compared with SSLDRs, but it is of note that over half of patients with serrated polyps have them only in the distal colon,¹²³ which could subject PSPDRs to gaming with prospective use. Data from the New Hampshire Colonoscopy Registry also demonstrated that SSL detection predicts PCCRC independent of ADRs.¹²⁸ The unadjusted risks of PCCRC were 1.4%, .6%, .6%, .4% and .3% with SSLDRs of $<1.0\%$, 1 to $<2.0\%$, 2.0 to $<4.0\%$, 4.0 to $<6.0\%$, and $\geq 6.0\%$, respectively. Approximately one-third of endoscopists (33.8% [50/148]) had adequate ADRs but SSLDRs $<6\%$.

One challenge with the SSLDR is that the prevalence of SSLs is lower than that of conventional adenomas, so that substantial procedure volumes will be required for some physicians to determine with confidence if detection is clearly adequate or suboptimal. This same issue impacts the reliability of ADR measurement⁹⁷ but does not negate the value of measurement. It seems reasonable to report the SSLDR to colonoscopists, with the expectation that the confidence interval around the SSLDR will narrow with continued measurement. Assessment and reporting of SSLDR performance over longer time periods than used for the ADR may be appropriate.

Based on available evidence, we recommend a current minimum threshold for the SSLDR of 6%. This is expected

to be revised upward as evidence of increasing detection occurs. Although evidence is limited, we consider that an SSLDR in FIT-positive patients of 6% (same target recommended for the SSLDR in a general population measurement) is appropriate, as there is little evidence that FIT detects serrated lesions, and few data on the yield of serrated lesions in FIT positive patients.¹²⁹ mt-sDNA does detect some serrated lesions based on methylation markers included in the test, but an appropriate target for SSLDRs in this population is currently uncertain. One recent study found a 20.5% prevalence of SSLs in mt-sDNA-positive patients.¹³⁰

We recommend that as groups of endoscopists using the same pathology service begin measuring SSLDRs, they review the range of SSLDRs across the endoscopy group relative to ADRs. If SSLDRs are low across the entire group, particularly in the setting of adequate ADRs, a review of SSL diagnoses with group endoscopists and/or local pathologists is needed.

Withdrawal time.

8. *Average withdrawal time in normal colonoscopies without biopsy sampling or polypectomies in persons aged ≥ 45 years undergoing screening, surveillance, or diagnostic colonoscopy. Patients with positive non-colonoscopy screening tests, genetic cancer syndromes (eg, polyposis), IBD, or undergoing colonoscopy for therapy of known neoplasms are excluded from the calculation.*

Strength of recommendation: 2A

Performance target: ≥ 8 minutes

Measure type: process

The recommended minimum average withdrawal time in normal colonoscopies without polypectomy, biopsy sampling, or therapy reflects the best evidence available regarding the time most colonoscopists need to apply careful and detailed inspection of the colon, from the appendiceal orifice to completion of retroflexion in the rectum. The first recommendation for withdrawal time made in 2002²⁹ recommended an average of 6 to 10 minutes in normal colonoscopies, based on the observation of 2 physicians participating in a miss rate study who had mean withdrawal times of 8 minutes and the lowest observed miss rates among 26 endoscopists in the study.¹³¹ In 2006, the recommendation for minimum average withdrawal time was changed to 6 minutes³⁰ on the basis of a landmark study showing that in a group of private practice gastroenterologists performing colonoscopy, 6 minutes of withdrawal time in normal colonoscopies was associated with reasonable separation between high- and low-level detectors.²⁶ Since 2006, but particularly since 2015, considerable evidence has demonstrated that optimal detection typically requires at least 8 to 9 minutes average withdrawal time in normal colonoscopies^{26,132-146} (Table 11). This evidence includes retrospective data showing that prevention of PCCRC is optimized at withdrawal times of at least 8 to 9

minutes.¹⁴⁷ Observational studies suggest that overall detection of adenomas is optimized at 8 to 9 minutes or longer^{26,132-146} (Table 11), as is detection of serrated lesions.^{135,138,142} A parallel-design randomized trial comparing 6 with 9 minutes found 9 minutes to be superior for detection,¹⁴⁵ as did a randomized tandem study comparing adenoma miss rates at 9 minutes versus 6 minutes.¹⁴⁶

Importantly, withdrawal time by itself is not an adequate measure of detection performance or skill. Rather, the primary measures of detection performance are ADR and SSLDR. Withdrawal time cannot substitute for ADR or SSLDR. Withdrawal time should be measured and recorded in clinical practice, and if ADR or SSLDR are low, an accompanying short withdrawal time suggests inadequate withdrawal technique. Corrective measures designed to improve ADR and SSLDR should focus on an optimized examination technique, which consists of systematic attempts to expose the mucosa proximal to each haustral fold, flexure, and valve in the colorectum; achieving adequate distention of the colon; and intraprocedural cleansing to expose mucosal surfaces covered by fluid collections, bubbles, or particulate debris.^{148,149} The point is that application of high-quality inspection techniques requires an average of at least 8 to 9 minutes.

There is some evidence that mucosal-exposure devices (specifically Endocuff Vision [Olympus America Corporation, Center Valley, Pa, USA]) can allow faster examination during withdrawal without compromising detection.¹⁵⁰ Additional study of this concept is needed.

The recommendation that the average minimum withdrawal time should be at least 8 to 9 minutes in normal colonoscopies should not be translated to mean that best practice or the standard of medical care requires that every withdrawal time should last ≥ 8 minutes. On the other hand, if ADR and/or SSLDR are below the minimum recommended threshold and accompanied by an average minimum withdrawal time of < 8 minutes, this could be construed as evidence of an inadequate withdrawal technique. Thus, low ADR accompanied by a short average withdrawal time should be considered an indication to evaluate and correct the inspection technique.

Resection Indicators

Documentation of lesion features and resection method indicator.

9. *Percentage of polyp resections for which the report documents the lesion size, shape, location, and method of resection.*

Strength of recommendation: 3

Performance target: $\geq 98\%$

Measure type: process

Use of cold snare for 4- to 9-mm lesions.

10. *Percentage of 4- to 9-mm lesions that are resected using a cold snare.*

TABLE 11. Withdrawal times associated with optimal detection at colonoscopy

Reference	Year	No. of patients	Optimal withdrawal time (min)
Barclay et al ¹²⁶	2006	2053	>6
Barclay et al ¹³²	2008	2325	>8
Overholt et al ¹³³	2010	15,955	>6
Benson et al ¹³⁴	2010	550	>6
Liang et al ¹³⁵	2012	18,003	Longer is better
Jover et al ¹³⁶	2013	4539	>8
Lee et al ¹³⁷	2013	31,088	10
Butterly et al ¹³⁸	2014	7972	9
Kashiwagi et al ¹³⁹	2017	1009	9
Yun et al ¹⁴¹	2018	5370	>9
Patel et al ¹⁴²	2018	10,196	11
Cavicchi et al ¹⁴³	2019	11,682	>8
Jung et al ¹⁴⁴	2019	724	9
Zhao et al ¹⁴⁵ (randomized controlled trial)	2020	1027	9
Zhao et al ¹⁴⁶ (randomized controlled trial)	2022	733	9
Desai et al	2022	1142	Increased adenoma detection rate up to 13

Strength of recommendation: 1A

Performance target: $\geq 90\%$

Measure type: process

The U.S. MSTF on CRC¹⁵¹ and the European Society of Gastrointestinal Endoscopy¹⁵² have created detailed recommendations for the resection of colorectal neoplasms. These recommendations cover the assessment and resection of the full range of colorectal neoplasms, including assessment and characterization of neoplasia, selection of resection methods, and optimal methodology for resection. Herein, we focus on quality measurement.

The writing committee considered a range of potential quality indicators for resection and now recommends 2 indicators that are characterized by feasibility of measurement, evidence of variable practice, and/or agreement among expert endoscopists regarding best practice. Both have substantial clinical relevance.

The first indicator asks that colonoscopists report for all polyps their size, shape, location in the colon by segment (or distance in centimeters from the anus for left-sided colon polyps), and the method of removal (ie, cold snare, cold forceps, hot snare, hot forceps, cold EMR, hot EMR, etc), although we note that hot forceps play no role in colorectal neoplasia resection except for avulsion during hot EMR or the removal of a flat polyp overlying fibrosis in the case of a recurrence or a previously partly resected polyp.

- **Size:** Size is an important parameter to record because it drives surveillance. The use of terms such as “small” is discouraged. Terminal digit rounding¹⁵³ is discouraged, and polyps ≥ 10 mm in size should be photographed with a snare of a known size fully opened and placed

over and against the polyp.¹⁵¹ Smaller polyps can be photographed using the same technique or by placing the tip of the snare sheath (diameter of 2.4 mm) up against the polyp base. Polyps in the same colorectal segment can be recorded with a range of sizes and shapes (eg, 4 flat and sessile polyps 2–4 mm in size removed by cold snare). Polyps ≥ 10 mm should be described individually. If multiple polyps ≥ 10 mm are removed from the same section and by the same method, with similar histologic predictions, they may be grouped together in the report. Certainly, any lesion, irrespective of size, that suggests advanced histology or endoscopic features of cancer (submucosal invasion or deeper) based on morphology or pit pattern analysis should be individually submitted for pathology and not combined in the same bottle as polyps from different segments.

- **Shape:** With regard to polyp shape, the Paris classification is recommended.¹⁵⁴ Use of the terms “sessile,” “flat,” and “pedunculated” is also acceptable. From the perspective of management of unexpected malignancy, the most important distinction is between pedunculated and nonpedunculated, because the histologic features that drive the decision for adjuvant surgical therapy vary slightly between these groups.¹⁵⁵ Interobserver agreement in differentiation of Paris IIa from Is lesions is poor and by extension so is the differentiation of “flat” from “sessile.”¹⁵⁶ Regardless, careful assessment of polyps for these features helps emphasize the extreme subtlety of many lesions and therefore the need for very careful inspection of the entire colorectum. Laterally spreading lesions, which grow laterally

along the colon wall for >1 cm, can be described by their specific morphology.^{151,152} An accurate assessment of morphology, together with colorectal location (colon vs rectum), can guide decisions regarding piecemeal versus en-bloc resection.^{151,152}

- **Location:** Polyp location should be recorded because it facilitates identification of polyp resection scars at surveillance, is essential when malignancy is suspected or reported unexpectedly, and is important to identify serrated polyposis syndrome.
- **Resection method:** Reporting the resection method is essential. Resection methods, particularly in the use and type of cautery, differ in their adverse event rates. Resection methods also differ in rates of completeness and recurrence, with forceps associated with higher incomplete resection rates of lesions >3 mm and cold EMR having higher recurrence rates for adenomas ≥20 mm in size.¹⁵⁷ Clip placement to treat or prevent hemorrhage is associated with artifacts at the follow-up examination.¹⁵⁸ Clip artifacts can be accurately distinguished from residual polyp by high-definition imaging,¹⁵⁹ but confirmation of a clip artifact is made easier by an accurate initial report of clip placement. Thus, all therapeutic steps of lesion resection should be described in the procedure report, including naming all specific devices and whether each resection step used electrocautery.

The second quality of resection indicator recommended is the percentage of lesions 4 to 9 mm in size removed by cold snare polypectomy. The first principle guiding the optimal resection of lesions in this size range is the extremely low risk of submucosally invasive cancer, which has decreased over time in successive publications.¹⁶⁰ The advantage of cold over hot resection is the near elimination of perforation and delayed hemorrhage,¹⁶¹⁻¹⁶⁴ which seems important for a set of lesions that are unlikely to harm patients in the near term. Indeed, the prevalence of adenomas is much higher than the lifetime risk of CRC, so that most patients with adenomas will never develop cancer. This is an important rationale for resecting lesions with a minimal risk of harm. Cold snare resection is associated with a more superficial resection plane than hot snare resection,^{165,166} which may underlie the higher risk of residual polyp when cold EMR is used to remove large adenomas.¹⁵⁷ However, randomized trials have indicated that complete resection rates using cold snaring for lesions <10 mm are comparable with hot snaring.¹⁶⁷⁻¹⁷⁴ Accurate technique and snare placement are more important than the use of specialty thin wire versus standard snares.¹⁷⁵ The indicator excludes lesions <4 mm, because evidence indicates that cold forceps and cold snaring are comparably effective for lesions up to 3 mm in size,¹⁷⁶⁻¹⁸² and some practitioners prefer cold forceps. However, cold forceps are less effective than cold snaring for lesions >3 mm in size.¹⁷⁶⁻¹⁸² Thus, cold snaring is the technique of choice for lesions 4 to 9 mm in size. Pedunculated lesions in this size range can also be removed safely and effectively by cold snaring.^{183,184} Despite this,

many endoscopists use cold forceps for lesions >3 mm in size, indicating both substantial evidence of variable practice with regard to resection technique for lesions 4 to 9 mm and considerable room for improvement. Many patients have 1 or more lesions ≤3 mm and 1 or more lesions 4 to 9 mm in size. Use of cold snaring for the entire range of lesions <10 mm in size saves the use of cold forceps and reduces plastic waste associated with colonoscopy.¹⁸⁵

Inadequate lesion resection and variation in resection quality are major issues in colonoscopy quality. The committee encourages developing internal institutional programs that evaluate resection performance using polypectomy assessment tools and providing periodic feedback to endoscopists. A detailed evaluation of PCCRC suggests that a significant minority of PCCRCs result from ineffective resection of advanced lesions.¹⁸⁶⁻¹⁸⁸ Biopsy sampling of the margins of lesions that appeared to be completely resected showed that residual neoplasia may still be present and that the risk is operator-dependent. Efficacy of complete resection varied by 3-fold among operators in 1 study.¹⁸⁹ An assessment of resection competency by blinded review of video recordings found that assessed competency also varied 3-fold, with some operators having rates of competent resection as low as 30%, and no correlation between ADR and competency of resection.³³

The best approach to assess resection competency is through real-time assessment by a monitor or by expert review of video recordings. Two scales have been validated for this purpose, including the Direct Observation of Polypectomy Skills¹⁹⁰ and the simpler and shorter Cold Snare Polypectomy Assessment Tool¹⁹¹ for the assessment of cold snare technique only. The writing committee of the ASGE/ACG Task Force considered that a broad recommendation to systematically evaluate all U.S. endoscopists with these tools would be challenging to implement because video recording is not widely available in the United States and the practice of real-time monitoring would be viewed as costly and impractical by many centers. Nonetheless, we encourage endoscopy centers to invest in recording equipment that can be used in monitoring of both inspection and resection quality.

In its last recommendations, the ASGE/ACG Task Force recommended that quality monitoring should evaluate the fraction of nonpedunculated lesions <2 cm that are referred for surgical resection as a quality indicator.³¹ This general topic is still appropriate for review in quality programs, although the method of audit can be challenging, and we are not including this indicator in this update. Endoscopic resection is the preferred method over surgical resection for all benign colorectal neoplasms regardless of size, shape, or location, with the possible exception of lesions invading the appendiceal orifice for which the entire margin cannot be exposed during colonoscopy.¹⁵¹ Endoscopic resection of benign neoplasms is associated with lower morbidity and mortality and lower costs than surgical resection.¹⁹²⁻¹⁹⁶ If feasible, one approach is to collaborate with the local

pathology department to review the pathology of all surgical colorectal resections and determine whether a local issue of inappropriate referral of benign lesions for surgery exists.

POSTPROCEDURE INDICATORS

Use of appropriate screening and surveillance intervals (priority indicator).

11. *Frequency with which colonoscopies follow recommended postpolypectomy and post-cancer resection surveillance intervals and frequency of 10-year intervals between screening colonoscopies in average-risk patients who have negative examination results and adequate bowel cleansing.*

Strength of recommendation: 1C

Performance target: $\geq 90\%$

Type of measure: process

Optimal performance of colonoscopy means it is both effective in preventing CRC and cost-effective. Optimal results can be achieved through optimized detection and resection of neoplasia during the procedure followed by continued screening or surveillance using evidence-based intervals. Currently, a negative screening colonoscopy should be followed by repeat examinations at an interval of 10 years.¹ Shorter intervals for screening are appropriate only for inadequate bowel preparation (in cases of inadequate preparation, a repeat colonoscopy with adequate preparation should be performed within 1 year) or if patients have a high-risk family history, defined as multiple first-degree relatives with CRC or advanced lesions or a first-degree relative with CRC or an advanced precancerous lesion at age <60 years, for which a 5-year interval is appropriate.¹ Current recommendations for postpolypectomy surveillance³² and post-CRC resection⁵³ in the United States are summarized in documents from the U.S. MSTF. Performing high-quality colonoscopy that optimizes benefit, minimizes harm, and maximizes cost-effectiveness includes an obligation to know and follow these recommendations for screening and surveillance intervals.

Noncompliance with guidelines for screening and surveillance intervals has been a longstanding issue.¹⁹⁷⁻²⁰⁷ A recent meta-analysis found that 17% to 25.7% of screening colonoscopies are performed more frequently than indicated or without an adequate indication for early repeat.¹⁹⁷ In community practice, there is substantial overuse of surveillance colonoscopy among low-risk subjects and underuse among subjects with high-risk precancerous lesions.¹⁹⁷⁻²⁰² Modeling indicates that surveillance contributes to reductions in CRC incidence and is cost-effective, including high-intensity surveillance in high-risk patients.²⁰⁸ Reasons for noncompliance with polyp surveillance guidelines have been surveyed.²⁰³⁻²⁰⁶ Rationales reported for overuse include the perception that patients have risk factors not addressed by guidelines, lack of guideline knowledge, fear of missed neoplasia, and lack of confidence about the strength

of underlying research supporting recommendations.²⁰³⁻²⁰⁶ However, the evidence supporting current recommendations is substantial,³² and U.S. recommendations include shorter and thus more-aggressive intervals than those used elsewhere in the world, which are based on review of the same evidence.^{209,210} Posters summarizing the postpolypectomy recommendations are available for placement in the endoscopy unit.³² Clinical decision support tools have been shown to improve compliance with guideline recommendations.^{211,212}

Adverse events.

12. *Proportion of serious adverse events (SAEs; perforation, postpolypectomy bleeding, and mortality) associated with colonoscopy that are tracked, documented, and reviewed by a quality improvement committee to assess for system and clinical areas of improvement.*

Strength of recommendation: 1C

Performance target: $\geq 95\%$

Measure type: process

Adverse events in colonoscopy span a range of outcomes. For colonoscopy, SAEs include perforation, postpolypectomy bleeding, cardiovascular events related to sedation, unplanned hospitalization, and mortality.²¹³ SAEs are reported to be under 1% across large integrated healthcare delivery systems.²¹⁴ In a large integrated healthcare organization in Washington State, SAEs (perforation, bleeding, myocardial infarction, stroke, splenic injury) within 30 days after colonoscopy fluctuated between .2 (myocardial infarction) and .8 (perforation) per 1000 screening colonoscopies and between .4 (myocardial infarction) and 1.1 (bleeding) per 1000 follow-up colonoscopies.²¹⁵ Most serious non-GI postcolonoscopy events are expected based on background event rates and are not attributable to the colonoscopy.²¹⁶

Endoscopy units must identify, track, and document SAEs related to colonoscopy. Although some events can be immediately identified, other events may not be evident until after discharge from the endoscopy unit. Strategies to capture delayed SAEs include using predefined billing codes or natural language processing within an electronic health medical record, in some cases across multiple healthcare systems. A second, and more common, modality is a postprocedure phone call. Several regulatory bodies, such as The Joint Commission, require a phone call within 48 hours of a procedure with anesthesia support²¹⁷; at the same time, guidance on procedures where moderate or deep sedation is used are not available. Although the optimal timing and frequency of these phone calls is not clearly defined and is impacted by many factors such as staffing resources, endoscopy units should achieve a 98% rate of attempting to call patients within 72 hours of their colonoscopy. Finally, SAEs can have devastating consequences for patients, providers, and healthcare teams. Consequently, when they occur, a focused approach should be used to review, analyze, and develop interventions to help prevent or minimize such events from

occurring in the future. An appropriate and recommended response to SAEs requires investigation, comprehensive systematic review, convening a group to conduct a root-cause analysis for identifying contributory factors, developing corrective actions in areas where improvement can be made to prevent future events, and implementing system improvements or education and remediation.²¹⁸⁻²²¹

Perforation can occur during or soon after colonoscopy, with over half diagnosed by the endoscopist.²²² About 5% of perforations associated with colonoscopy are fatal.²²³⁻²²⁵ Perforation is most common in the cecum and sigmoid colon.²²⁶⁻²²⁸ Common etiologies are barotrauma, direct mechanical injury through endoscope advancement or dilation, and thermal or electrical injury during a therapeutic maneuver.^{226,229} Perforation in screening examinations is lower, with a reported incidence of .04%²³⁰; perforations increase to .016% to .8% for diagnostic colonoscopies²³¹ and to .02% to 8% for therapeutic colonoscopies.²³¹ Patients with diverticulosis²³² and irritable bowel syndrome^{233,234} as well as those taking corticosteroids are at an increased risk of perforation. Nongastroenterologists performing colonoscopy²³⁵ and low-volume endoscopists^{236,237} are associated with higher perforation rates. Polypectomy²³¹ with electrocautery increases the risk of perforation.²³⁸

The factors that decrease perforation risk include not exerting force with the endoscope against fixed resistance, removing loops, using a flexible instrument (eg, pediatric colonoscope or upper endoscope) in narrowed sigmoid colons, using cold snare polypectomy instead of cautery in the resection of diminutive polyps,^{162,174,238-240} insufflation with carbon dioxide,²⁴¹ and submucosal injection during EMR.²⁴² Endoscopists who recognize a perforation during the procedure should attempt closure with through-the-scope clips²⁴³ or large clips that are mounted over the end of the endoscope.²⁴⁴ All perforations should be monitored by the endoscopy unit medical director and reviewed by a quality improvement committee. This approach can lead to changes in processes and opportunities for endoscopist education, which can improve practices that reduce future risk.

Bleeding is the most common adverse event of polypectomy.^{224,245,246} Bleeding can be immediate (during the procedure) or delayed (after release from the endoscopy unit). Risk factors include polyps >1 cm in size,²⁴⁶⁻²⁴⁸ high number of polyps removed,²⁴⁹⁻²⁵¹ proximal colon location,^{252,253} certain comorbidities,^{251,254} and use of antiplatelet and/or anticoagulant medications.²⁴⁹ Older observational data on bleeding rates using fixed-power output generators found that low-power coagulation current was associated with increased delayed bleeding and less immediate, with cutting or blended current associated with more-immediate and less-delayed bleeding.^{255,256} A randomized trial of forced coagulation current versus an alternating cut-coagulation current (Endocut; Erbe, Stuttgart, Baden-Württemberg, Germany) using microprocessor-controlled generators found

similar rates of delayed bleeding and higher rates of immediate bleeding with Endocut.²⁵⁷ Endoscopists should follow guidelines for managing anticoagulant and antiplatelet medications before and after colonoscopy.^{258,259} Cold snare polypectomy for small polyps (<9 mm) reduces delayed hemorrhage.^{162,174,239,240,260} Prophylactic clipping of resection sites should be performed when feasible for lesions >2 cm located proximal to the splenic flexure that were removed using electrocautery (all 3 criteria fulfilled).^{261,262} Delayed hemorrhages requiring hospitalization, transfusion, and repeat endoscopic, radiographic, or surgical procedures to control bleeding warrant a review of the polypectomy technique, appropriate use of prophylactic measures, and other related case aspects.

Immediate bleeding should be treated by endoscopic means and rarely requires interventional radiology or operative treatment. Delayed bleeding frequently stops spontaneously.²⁶³ In-hospital observation is appropriate for ongoing bleeding or if the patient has comorbidities, resides far away, or has transportation challenges. Repeat colonoscopy is optional in patients in whom bleeding has ceased. Patients continuing to demonstrate overt GI bleeding (ie, hematochezia or melena) require prompt repeat colonoscopy.²⁶³ Treatment can entail clip application or epinephrine injection in combination with multipolar cautery.^{263,264} Repeat postpolypectomy bleeding is rare once it has stopped spontaneously or has been treated with endoscopic therapy.

Most deaths directly attributable to colonoscopy are cardiopulmonary events related to anesthesia or sedation.²¹³ Although all-cause mortality within 30 days of colonoscopy occurs in .07% of patients, nearly all deaths are linked to underlying comorbidities such as cardiopulmonary disease, cirrhosis, and/or neurologic diseases.²¹³ Any death after colonoscopy warrants a detailed investigation and review by the institution's quality committee to ascertain underlying causes, determine if the death was preventable, and what improvements can be implemented moving forward.

QUALITY INDICATORS FOR COLONOSCOPY IN IBD

IBD intraprocedure colonoscopy indicators

UC disease activity scores.

- Percentage of colonoscopies performed for the indication of UC in which a formal assessment of disease extent and activity (Mayo Endoscopic Score [MES], Modified Mayo Endoscopic Score [MMES], Ulcerative Colitis Endoscopic Index of Severity [UCEIS], or Ulcerative Colitis Colonoscopic Index of Severity) is recorded.

Strength of recommendation: 3

Performance target: $\geq 90\%$

Measure type: process

Documenting the extent and severity of endoscopic inflammation in the colon in patients with UC is essential

in the classification of disease severity, prognosis, and risk for future development of colorectal neoplasia.²⁶⁵ In general, the endoscopic extent of disease correlates with patient-reported outcomes, laboratory tests, and prognosis. In addition, disease extent and severity are important factors when choosing medical therapy. The report can specify the extent by description of involved segments or use the Montreal classification to document extent of disease.²⁶⁶ In the Montreal system, endoscopic disease limited to the rectum is E1, left-sided colitis is E2, and any disease proximal to the splenic flexure is E3.

Endoscopic disease activity correlates with prognosis and risk of developing colorectal neoplasia. Objective markers of endoscopic disease activity are needed because symptoms often do not correlate with endoscopic findings. In 2021, the International Organization for the Study of Inflammatory Bowel Disease updated recommendations for treatment targets in adult patients with IBD.²⁶⁷ Mucosal healing is now an important clinical target associated with long-term clinical remission, avoidance of colectomy, and corticosteroid-free clinical remission.²⁶⁸ In UC, endoscopic assessment can be performed using sigmoidoscopy or colonoscopy.

Several scoring systems are available to grade endoscopic disease activity.²⁶⁹ The MES, first reported in 1987,²⁷⁰ is easily implemented in clinical practice and, although not validated, is commonly used and accepted by the U.S. Food and Drug Administration. Several mucosal findings comprise the MES, including erythema, assessment of vascular pattern, presence of friability, spontaneous bleeding, erosions, or ulcerations. Scores range between 0 and 3. The MMES was introduced in 2015 to quantify the extent of colonic involvement.²⁷¹ In the MMES, the colon is divided into 5 segments, and the score for each segment is added to give a modified score, which is multiplied by the maximal extent of inflammation and divided by the number of segments with active inflammation. The MMES correlates with clinical, biologic, and histologic activity and allows a better assessment of partial healing but is not validated.

An alternative endoscopic scoring system for UC first developed in 2012 is the UCEIS.^{272,273} For this tool, 3 endoscopic findings comprise the 8-point scale and include assessment of the vascular pattern,^{265,266} presence of bleeding,²⁶⁵⁻²⁶⁸ and erosions and/or ulcers^{265,266} scored in the most severely affected part of the colon. Friability is not a component of the UCEIS. The UCEIS is validated, has satisfactory interobserver agreement, is responsive to treatment effects, and is able to predict medium- to long-term outcomes of patients in clinical remission.

The Ulcerative Colitis Colonoscopic Index of Severity was developed in 2013 and is calculated by evaluating segmental scores using 4 different variables: granularity, vascular pattern, ulceration, and bleeding and/or friability.²⁷⁴ Although validated and with high interobserver

agreement, obtaining the final score is complex and may not be simple to use in clinical practice.

Other endoscopic scoring tools are under development to assess mucosal healing.²⁷⁵ Video training in the use of scales is available.²⁶⁹ Training programs have demonstrated improved inter-rater agreement seen with expert endoscopists.²⁷⁶

An MES of 0 and 1 are both associated with positive patient outcomes in treatment trials. In STRIDE II, the MES or UCEIS were recommended to assess endoscopic activity with endoscopic healing defined as a MES of 0 and UCEIS ≤ 1 .²⁶⁷

Crohn's disease activity score.

14. *Percentage of colonoscopies performed for the indication Crohn's disease (CD) in which a formal disease activity score (Crohn's Disease Endoscopic Index of Severity [CDEIS], Simple Endoscopic Activity Score in Crohn's Disease [SES-CD], or Rutgeerts score) is reported.*

Strength of recommendation: 3

Performance target: $\geq 90\%$

Type of measure: process

Investigators have advocated for both symptomatic and endoscopic assessments of CD to best quantify response to therapy. Endoscopic assessment of disease activity is an essential aid to clinical practice. Although the CDEIS and SES-CD have been validated, a minimally important clinical change in score has not been defined for either instrument.

The CDEIS was developed in 1989.²⁷⁷ Components include 9 separate lesions: pseudopolyps, healed ulceration, frank erythema, frankly swollen mucosa, aphthoid ulceration, superficial shallow ulceration, deep ulceration, nonulcerated stenosis, and ulcerated stenosis. CDEIS scoring is relatively complex, with total scores ranging from 0 to 44 and higher scores denoting worse disease activity. High intraclass correlation coefficients for intra-rater and interrater reliability of .96 and .86, respectively, were observed for total CDEIS scores during the index development. In a second study, the intrarater correlation was .89 and inter-rater correlation .71.²⁷⁸ Construct validity of the 2 ranges was from .75 to .83. Responsiveness has been measured as a correlation between changes in mean and global evaluation of disease with a correlation coefficient (r) of .72.²⁷⁹

The SES-CD was developed to overcome concerns associated with the complexity of the CDEIS. The components of the SES-CD include ulcer size, proportion of ulcerated surface, proportion of the surface area affected by any disease lesion, and stenosis.²⁸⁰ Each component is graded from 0 to 3, and a total score is calculated as the sum of the items for all segments of the colon and terminal ileum. The correlation coefficient for intrarater reliability was .91 for the CDEIS and .98 for the SES-CD.²⁸⁰ In a second study, the intrarater correlation was .91.²⁸¹ The responsiveness to change was evaluated with repeat colonoscopy at an

average of 4 months after baseline, and changes measured by the 2 indices were highly correlated with an r of .83.²⁸²

Although both scoring systems are widely available for use, the SES-CD is increasingly favored for both eligibility and outcome assessment given its relative simplicity. The BRIDGE (Building Research in Inflammatory Bowel Disease Globally) group used a modified Delphi approach to identify elements of high-quality IBD endoscopy reporting.²⁸³ The panel noted that the use of the SES-CD was appropriate in clinical practice, although they recognized that the primary advantage was the use of standardized descriptive terminology of endoscopic findings rather than quantitative assessment. The first STRIDE guideline²⁸⁴ recommended the absence of ulcers as an adequate endpoint in routine clinical care, but the more recent STRIDE-II guideline endorsed SES-CD. Endoscopic healing is reflected by an SES-CD <3 points or an SES-CD ulceration subscore of 0.²⁶⁷

The Rutgeerts score grades early neoterminal ileal lesions to predict postsurgical outcomes and identify patients for whom therapy escalation may be necessary.²⁸⁵ Lesions are graded on a 5-point scale of increasing severity where a grade of i0 indicates no lesions in the distal ileum, i1 indicates ≤ 5 aphthous lesions in the distal ileum, i2 indicates >5 aphthous lesions in the distal ileum with normal mucosa between lesions or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis, i3 indicates diffuse aphthous ileitis with diffusely inflamed mucosa, and i4 indicates large ulcers with diffuse mucosal inflammation or nodules or stenosis. Endoscopic recurrence is defined as a score of $\geq i2$. Currently, an assessment of the reliability, responsiveness, validity, and feasibility of the Rutgeerts score is required, but the scale has proven straightforward for clinical practice.

In summary, we recommend the use of a specific scoring system to assess disease activity for both UC and CD. This is essential in optimizing accurate classification of disease severity and determining prognosis and risk of adverse events. The most used scores based on clinical experience and ease of use are shown in Table 12.

IBD postcolonoscopy quality indicators

UC surveillance colonoscopy interval.

15. *Frequency of appropriate recommendation for a follow-up surveillance colonoscopy interval for patients with UC and/or indeterminate colitis undergoing dysplasia screening without dysplasia detected.*

Strength of recommendation: 1C

Performance target: $\geq 90\%$

Type of measure: process

Patients with UC and colonic CD have an increased risk of CRC.²⁸⁶ CRC associated with IBD has poorer outcomes compared with sporadic CRC, including younger age at onset and worse survival.^{287,288}

Routine surveillance colonoscopies are recommended for IBD patients with colonic disease extending beyond

the rectum after 8 years of disease to monitor for the development of colonic dysplasia or neoplasia.^{265,286,289,290} For patients with IBD and concomitant primary sclerosing cholangitis, initiation of surveillance is recommended at the time of a diagnosis of primary sclerosing cholangitis.^{265,286,289,290} However, data supporting clinical or mortality benefits of such strategies are limited, and the quality of available evidence is low.²⁹¹

We recommend that the appropriateness of recommended surveillance intervals should be measured after colonoscopy in patients with UC or indeterminate colitis with no dysplasia. The basis for assessing appropriate intervals is presented in Table 13. The recommendations assume an examination of the entire colon with adequate bowel preparation. Uncertainty exists regarding whether dye-spray or electronic chromoendoscopy adds any benefit when using a high-definition colonoscope, and we suggest high-definition colonoscopy complemented with 1 modality of chromoendoscopy with targeted biopsy sampling of suspicious areas.^{265,286,289,290}

Table 13 presents a compilation of 4 clinical guidelines or clinical practice updates to develop a summary guideline.^{265,286,289,290} We considered that the ACG guideline had a maximum interval of 3 years,²⁶⁵ whereas 3 other guidelines and updates allowed up to 5 years between colonoscopies in select situations.^{286,289,290}

The recommendations are based on known risk factors for IBD-associated CRC including duration of disease, disease extent, age at onset, degree of inflammation, presence of colonic strictures, concomitant primary sclerosing cholangitis, family history of CRC, and male sex.²⁹² Shorter time intervals are recommended for those with high-risk features, whereas longer time intervals can be recommended for those with limited risk and who have achieved mucosal healing (Table 13).

CORRECTION OF POOR PERFORMANCE

The primary purpose of measuring colonoscopy quality indicators is to improve patient care through identification of suboptimal performance and implementation of interventions that address deficiencies. Improvement in colonoscopy quality metrics has been documented for bowel preparation quality, polyp detection and resection, and compliance with surveillance recommendations.²⁹³⁻²⁹⁸ Improvement in the ADR is associated with a reduced risk of PCCRC and cancer-related death.²⁹⁹

Although a full discussion of approaches to improve colonoscopy quality is beyond the scope of this document, key principles are discussed. Optimal adenoma detection depends on adequate bowel preparation, a withdrawal technique that maximizes mucosal exposure, high-level recognition of subtle neoplasia, and complete resection of precancerous lesions. A critical first step in colonoscopy quality assurance is the audit and feedback of individual

TABLE 12. Suggested scoring systems for inflammatory bowel disease activity

Scoring scale	Disease	Scoring	Notes
Mayo Endoscopic Score	Ulcerative colitis	0: normal or inactive colitis	
		1: erythema, mild decrease in vascularity	
		2: friability, marked erythema, vascular pattern absent, erosions seen	
		3: ulcerations and spontaneous bleeding	
Simple Endoscopic Activity Score in Crohn's Disease	Crohn's disease	0: none	A score is documented from the ileum, right-sided colon, transverse, left-sided colon, and rectum.
		1: aphthous ulcers, <10% ulcerated surface, <50% affected surface, single narrowing passed	Maximum score is 12 per segment, with a total maximum of 60.
		2: larger ulcers, 10%-30% ulcerative surface, 50%-75% affected surface, multiple narrowings	
		3: very large ulcers, >30% ulcerated surface, >75% affected surface, narrowing cannot be passed	
Rutgeerts score	Crohn's recurrence in the neoterminal ileum after surgical resection of the terminal ileum	i0: no lesions, normal-appearing neoterminal ileum	Endoscopic remission i0 or i1; recurrence is i2-i4 with i3or i4 most likely to develop clinical relapse.
		i1: ≤5 aphthous ulcers in the neoterminal ileum	
		i2: >5 aphthous ulcers in the neoterminal ileum with normal-intervening mucosa or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis	
		i3: diffuse aphthous ileitis with diffusely inflamed mucosa	
		i4: diffuse inflammation with large ulcers, nodules, and/or narrowing	

TABLE 13. Timing of subsequent colonoscopy for patients with ulcerative/indeterminate colitis undergoing a screening colonoscopy with no dysplasia detected at the current colonoscopy

1 year	2-3 years	3-5 years
<ul style="list-style-type: none"> Primary sclerosing cholangitis (including after liver transplant) 	<ul style="list-style-type: none"> Prior resected visible dysplasia <5 y ago 	<ul style="list-style-type: none"> Mucosal healing on current examination and ≥2 examinations without dysplasia
<ul style="list-style-type: none"> Family history of colorectal cancer in first-degree relative aged <50 y 	<ul style="list-style-type: none"> Family history of colorectal cancer (but no first-degree relative aged <50 y) 	<ul style="list-style-type: none"> Overall disease extent affecting one-third or less of the colon
<ul style="list-style-type: none"> Prior invisible dysplasia <5 y ago 	<ul style="list-style-type: none"> Mildly active inflammation 	
<ul style="list-style-type: none"> Active inflammation (more than mild) 	<ul style="list-style-type: none"> Pseudopolyps (but not dense) 	
<ul style="list-style-type: none"> Dense pseudopolyps 		
<ul style="list-style-type: none"> Colonic stricture 		

physician performance, with most studies demonstrating feedback is associated with quality improvement.³⁰⁰⁻³⁰⁴ When individuals have ADRs below the recommended threshold, a variety of interventions has been found to be effective (Table 14).

Split-dose or same-day (preparation entirely the morning of the procedure) bowel preparation increased ADRs in randomized-controlled studies.³⁰⁵ A high-quality withdrawal technique includes cleaning pools of retained stool, fluid, and mucus; exposing hidden mucosa by systematically

TABLE 14. Interventions to improve adenoma detection rate

Intervention (with selected references)
Physician report cards ³⁰⁰⁻³⁰⁴
Public reporting of adenoma detection rate
Water assistance ^{312,313}
Second look, either retroflexion in the cecum or second forward look in the proximal colon ^{306,307}
Dynamic change in patient position ^{314,315}
High-definition endoscopes ³²³⁻³²⁵
Distal attachment devices ³⁰⁸⁻³¹¹
Enhanced imaging technology (eg, narrow-band imaging, i-SCAN, linked-color imaging, blue-laser imaging, chromoendoscopy, and/or methylene blue-MMX [Cosmo Pharmaceuticals, Dublin, Ireland] ^{293,326}
Computer-aided detection technologies ³³⁰⁻³³³
Split-dose bowel preparation ³⁰⁵
Nurse assigned to observe colonoscopy monitor ³⁴⁶
Focused educational interventions ³¹⁷⁻³²⁰
Leadership training in colonoscopy technique ³¹⁶

probing the proximal sides of folds; and achieving adequate distention of the entire colon.^{148,149} A second examination of the right-sided colon, with or without retroflexion, improves detection and is recommended.^{306,307} Distal attachment devices help expose mucosa and improve ADRs, as shown in many randomized trials.³⁰⁸⁻³¹¹ Other techniques associated with improved ADRs include water exchange during colonoscopy insertion^{312,313} and changing the patient's position during inspection to keep the examined segment nondependent.^{314,315} Adequate mucosal exposure and inspection require time, and a low ADR in combination with short average withdrawal times should be viewed as an indicator of ineffective withdrawal techniques that warrant correction.

Optimized mucosal exposure must be accompanied by training in the detection of subtle neoplasia, particularly SSLs. Randomized trials have demonstrated the effectiveness of educational interventions to improve ADRs.³¹⁶⁻³²⁰ The task force recommends instruction in the Paris classification³²¹ to emphasize the importance of flat and depressed lesions and a review of photographs of flat and depressed conventional adenomas and serrated lesions.³²²

High-definition endoscopes improve ADRs³²³⁻³²⁵ and are considered mandatory in current colonoscopy practice. Finally, technical adjuncts to improve ADRs can be considered. Electronic chromoendoscopy with second-generation narrow-band imaging (Olympus America Corporation) resulted in a higher ADR than white-light colonoscopy (odds ratio, 1.28, 95% confidence interval, 1.05-1.56) in a meta-analysis of randomized controlled studies,³²⁶ although older versions of narrow-band imaging and electronic chromoendoscopy did not significantly improve ADRs.³²⁷ Linked-color imaging (Fujifilm Corp, Valhalla, NY, USA) is also associated

with detection gains for both adenomas and SSLs.^{328,329} Artificial intelligence systems for detection of neoplasia have been recently approved in the United States with most randomized controlled studies demonstrating significant improvements in ADRs³³⁰⁻³³² and reductions in adenoma miss rates.³³³ Despite the convincing and consistent evidence from randomized trials, assessments of benefit in clinical practice settings have been negative in several instances.³³⁴⁻³³⁶ Generalizability to routine practice settings remains to be demonstrated convincingly. Successful programmatic colonoscopy quality assurance efforts with demonstrated improvements in patient outcomes have been outlined from the UK National Bowel Cancer Screening Programme,³³⁷⁻³⁴⁰ the Netherlands,³⁴¹ Poland,³¹⁶ Germany,³⁴² the U.S. Veterans Administration,³⁴³ and Kaiser Permanente Northern California.³⁴⁴

In summary, correction of poor performance begins with measurements of colonoscopy quality to identify specific areas of concern. Quality improvement may depend on the use of multifaceted interventions. As a last resort, removal of privileges to perform colonoscopy may be appropriate if satisfactory performance cannot be achieved, because colonoscopy quality is strongly associated with important patient outcomes, such as PCCRC incidence and mortality.^{21,22,92} These recommendations hold for colonoscopists in all specialties.³⁴⁵

DISCLOSURE

The following authors disclosed financial relationships: D. K. Rex: Consultant for Olympus Corporation, Boston Scientific, Braintree Laboratories, Norgine, GI Supply, Medtronic, and Acacia Pharmaceuticals; research support from Olympus Corporation, Medivators, Erbe USA Inc, and Braintree Laboratories; shareholder in Satisfai Health. T. Kaltenbach: Consultant for Verily Life Sciences and Olympus Corporation. U. Ladabaum: Advisor for Universal Dx, Kohler Ventures, Vivante Health, and Lean Health; consultant for Freenome, Guardant, Neptune, Media EarlySign, and Medtronic. T. R. Levin: Research support from Freenome, Inc. A. Shaikat: Consultant for Iterative Health. F. A. Farraye: Consultant for AbbVie, Avalo Therapeutics, BMS, Braintree Labs, Fresenius Kabi, GI Reviewers, GSK, IBD Educational Group, Iterative Health, Janssen, Pharmacosmos, Pfizer, Sandoz Immunology, and Viatrix; data and safety monitoring board for Lilly. S. Kane: Consultant for Boehringer Ingelheim, Bristol Meyers Squibb, InveniAI, Janssen, Fresenius Kabi, PredicatMed, Lilly, and Takeda; section editor for UpToDate. All other authors disclosed no financial relationships.

Prepared by:

Douglas K. Rex, MD, MASGE

Division of Gastroenterology and Hepatology

Department of Medicine

Indiana University School of Medicine

Indianapolis, Indiana, USA

Joseph C. Anderson, MD

Department of Medicine/Division of Gastroenterology
Geisel School of Medicine at Dartmouth
Hanover, New Hampshire, USA
Department of Medicine/Division of Gastroenterology
White River Junction VAMC
White River Junction, Vermont, USA
University of Connecticut School of Medicine
Farmington, Connecticut, USA

Lynn F. Butterly, MD

Geisel School of Medicine at Dartmouth
Hanover, New Hampshire, USA
Department of Medicine
Section of Gastroenterology and Hepatology
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, USA
New Hampshire Colonoscopy Registry
Lebanon, New Hampshire, USA

Lukejohn W. Day, MD

Division of Gastroenterology
Department of Medicine
University of California San Francisco
Chief Medical Officer
University of California San Francisco Health System

Jason A. Dominitz, MD, MHS, MASGE

Division of Gastroenterology
Department of Medicine
University of Washington School of Medicine
Seattle, Washington, USA
VA Puget Sound Health Care System
Seattle, Washington, USA

Tonya Kaltenbach, MD, MS, MASGE

Department of Medicine
University of California
San Francisco, California, USA
Division of Gastroenterology
San Francisco Veterans Affairs Medical Center
San Francisco, California, USA

Uri Ladabaum, MD

Division of Gastroenterology and Hepatology
Department of Medicine
Stanford University School of Medicine
Stanford, California, USA

Theodore R. Levin, MD

Kaiser Permanente Division of Research
Pleasanton, California, USA

Aasma Shaukat, MD, MPH, FASGE

Division of Gastroenterology
Department of Medicine

NYU Grossman School of Medicine

New York Harbor Veterans Affairs Health Care System
New York, New York, USA

Jean-Paul Achkar, MD

Department of Gastroenterology, Hepatology and Nutrition
Digestive Diseases Institute
Cleveland Clinic
Cleveland, Ohio, USA

Francis A. Farraye, MD, MSc, FASGE

Division of Gastroenterology and Hepatology
Mayo Clinic Florida
Jacksonville, Florida, USA

Sunanda V. Kane, MD, MSPH, FASGE

Division of Gastroenterology and Hepatology
Mayo Clinic Rochester
Rochester, Minnesota, USA

Nicholas J. Shaheen, MD, MPH, MASGE

Division of Gastroenterology and Hepatology
University of North Carolina
Chapel Hill, North Carolina, USA

Abbreviations: ACG, American College of Gastroenterology; ADR, adenoma detection rate; APC, adenoma per colonoscopy; ASGE, American Society for Gastrointestinal Endoscopy; CD, Crohn's disease; CDEIS, Crohn's Disease Endoscopic Index of Severity; CIR, cecal intubation rate; CRC, colorectal cancer; FIT, fecal immunochemical test; IBD, inflammatory bowel disease; MES, Mayo Endoscopic Score; MMES, Modified Mayo Endoscopic Score; mt-sDNA, multitarget stool DNA; MSTF, Multi-Society Task Force; PCCRC, postcolonoscopy colorectal cancer; PSPDR, proximal serrated polyp detection rate; SAE, serious adverse event; SES-CD, Simple Endoscopic Activity Score in Crohn's Disease; SSL, sessile serrated lesion; SSLDR, sessile serrated lesion detection rate; UC, ulcerative colitis; UCEIS, Ulcerative Colitis Endoscopic Index of Severity.

REFERENCES

1. Rex DK, Boland CR, Dominitz JA, et al. Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer. *Gastrointest Endosc* 2017;86:18-33.
2. Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. *JAMA* 2021;325:1965-77.
3. Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening 2021. *Am J Gastroenterol* 2021;116:458-79.
4. Wolf AMD, Fonham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. *CA Cancer J Clin* 2018;68:250-81.
5. Kahi CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. *Gastrointest Endosc* 2016;83:489-98.
6. Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. *Am J Gastroenterol* 2020;115:415-34.

7. Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. *Gastroenterology* 2015;148:639-51.
8. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. *N Engl J Med* 2000;343:1603-7.
9. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. *N Engl J Med* 2012;366:2345-57.
10. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. *N Engl J Med* 1993;329:1977-81.
11. Zauber AG, Winawer SJ, O'Brien MJ, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. *N Engl J Med* 2012;366:687-96.
12. Kahi CJ, Imperiale TF, Juliar BE, et al. Effect of screening colonoscopy on colorectal cancer incidence and mortality. *Clin Gastroenterol Hepatol* 2009;7:770-5; quiz 711.
13. Brenner H, Chang-Claude J, Seiler CM, et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. *Ann Intern Med* 2011;154:22-30.
14. Doubeni CA, Weinmann S, Adams K, et al. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. *Ann Intern Med* 2013;158:312-20.
15. Brenner H, Chang-Claude J, Jansen L, et al. Reduced risk of colorectal cancer up to 10 years after screening, surveillance, or diagnostic colonoscopy. *Gastroenterology* 2014;146:709-17.
16. Baxter NN, Goldwasser MA, Paszat LF, et al. Association of colonoscopy and death from colorectal cancer. *Ann Intern Med* 2009;150:1-8.
17. Baxter NN, Warren JL, Barrett MJ, et al. Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. *J Clin Oncol* 2012;30:2664-9.
18. Nishihara R, Wu K, Lochhead P, et al. Long-term colorectal-cancer incidence and mortality after lower endoscopy. *N Engl J Med* 2013;369:1095-105.
19. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. *Cancer* 2010;116:544-73.
20. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. *CA Cancer J Clin* 2014;64:104-17.
21. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. *N Engl J Med* 2010;362:1795-803.
22. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. *N Engl J Med* 2014;370:1298-306.
23. Ladabaum U, Shepard J, Mannalithara A. Adenoma and serrated lesion detection by colonoscopy indication: the ADR-ESS (ADR Extended to all Screening/Surveillance) score. *Clin Gastroenterol Hepatol* 2021;19:1873-82.
24. Rex DK. Colonoscopy: the current king of the hill in the USA. *Dig Dis Sci* 2015;60:639-46.
25. Bretthauer M, Loberg M, Wieszczy P, et al. Effect of colonoscopy screening on risks of colorectal cancer and related death. *N Engl J Med* 2022;387:1547-56.
26. Barclay RL, Vicari JJ, Doughty AS, et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. *N Engl J Med* 2006;355:2533-41.
27. Marratt JK, Dickens J, Schoenfeld PS, et al. Factors associated with surveillance adenoma and sessile serrated polyp detection rates *Dig Dis Sci*. 2017;62:3579-85.
28. Chen SC, Rex DK. Endoscopist can be more powerful than age and male gender in predicting adenoma detection at colonoscopy. *Am J Gastroenterol* 2007;102:856-61.
29. Rex DK, Bond JH, Winawer S, et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. *Am J Gastroenterol* 2002;97:1296-308.
30. Rex DK, Petrini JL, Baron TH, et al. Quality indicators for colonoscopy. *Gastrointest Endosc* 2006;63:S16-28.
31. Rex DK, Schoenfeld PS, Cohen J, et al. Quality indicators for colonoscopy. *Gastrointest Endosc* 2015;81:31-53.
32. Gupta S, Lieberman D, Anderson JC, et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. *Gastrointest Endosc* 2020;91:463-85.
33. Duloy AM, Kaltenbach TR, Keswani RN. Assessing colon polypectomy competency and its association with established quality metrics. *Gastrointest Endosc* 2018;87:635-44.
34. Elmunzer JB, Anderson MA, Mishra G, et al. Quality indicators common to all GI endoscopic procedures. *Gastrointest Endosc* 2024;100:382-94.
35. ASGE Endoscopy Unit Quality Indicators Taskforce; Day LW, Cohen J, Greenwald D, et al. Quality indicators for gastrointestinal endoscopy units. *VideoGIE* 2017;2:119-40.
36. Baxter NN, Sutradhar R, Forbes SS, et al. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. *Gastroenterology* 2011;140:65-72.
37. Vemulapalli KC, Wilder SW, Kahi CJ, et al. Long-term assessment of the cecal intubation rates in high-performing colonoscopists: time for review. *Clin Transl Gastroenterol* 2020;11:e00153.
38. Siau K, Hodson J, Ravindran S, et al. Variability in cecal intubation rate by calculation method: a call for standardization of key performance indicators in endoscopy. *Gastrointest Endosc* 2019;89:1026-36.
39. Early DS, Ben-Menachem T, Decker GA, et al. Appropriate use of GI endoscopy. *Gastrointest Endosc* 2012;75:1127-31.
40. Balaguer F, Llach J, Castells A, et al. The European panel on the appropriateness of gastrointestinal endoscopy guidelines colonoscopy in an open-access endoscopy unit: a prospective study. *Aliment Pharmacol Ther* 2005;21:609-13.
41. Vader JP, Pache I, Froehlich F, et al. Overuse and underuse of colonoscopy in a European primary care setting. *Gastrointest Endosc* 2000;52:593-9.
42. de Bosset V, Froehlich F, Rey JP, et al. Do explicit appropriateness criteria enhance the diagnostic yield of colonoscopy? *Endoscopy* 2002;34:360-8.
43. Terraz O, Wietlisbach V, Jeannot JG, et al. The EPAGE internet guideline as a decision support tool for determining the appropriateness of colonoscopy. *Digestion* 2005;71:72-7.
44. Morini S, Hassan C, Meucci G, et al. Diagnostic yield of open access colonoscopy according to appropriateness. *Gastrointest Endosc* 2001;54:175-9.
45. Bersani G, Rossi A, Ricci G, et al. Do ASGE guidelines for the appropriate use of colonoscopy enhance the probability of finding relevant pathologies in an open access service? *Dig Liver Dis* 2005;37:609-14.
46. Baron TH, Kimery BD, Sorbi D, et al. Strategies to address increased demand for colonoscopy: guidelines in an open endoscopy practice. *Clin Gastroenterol Hepatol* 2004;2:178-82.
47. Johnson DA, Barkun AN, Cohen LB, et al. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. *Gastrointest Endosc* 2014;80:543-62.
48. Hassan C, Bretthauer M, Kaminski MF, et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) guideline. *Endoscopy* 2013;45:142-50.
49. Hassan C, East J, Radaelli F, et al. Bowel preparation for colonoscopy: European Society of Gastrointestinal Endoscopy (ESGE) guideline—update 2019. *Endoscopy* 2019;51:775-94.
50. Rex DK, Imperiale TF, Latinovich DR, et al. Impact of bowel preparation on efficiency and cost of colonoscopy. *Am J Gastroenterol* 2002;97:1696-700.

51. Kluge MA, Williams JL, Wu CK, et al. Inadequate Boston Bowel Preparation Scale scores predict the risk of missed neoplasia on the next colonoscopy. *Gastrointest Endosc* 2018;87:744-51.
52. Clark BT, Protiva P, Nagar A, et al. Quantification of adequate bowel preparation for screening or surveillance colonoscopy in men. *Gastroenterology* 2016;150:396-405; quiz e14-5.
53. Kahi CJ, Boland CR, Dominitz JA, et al. Colonoscopy surveillance after colorectal cancer resection: recommendations of the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology* 2016;150:758-68.
54. Rex DK. Achieving cecal intubation in the difficult colon (with videos). *Gastrointest Endosc* 2022;95:568-72.
55. Liu TT, Meng YT, Xiong F, et al. Impact of an abdominal compression bandage on the completion of colonoscopy for obese adults: a prospective randomized controlled trial. *Can J Gastroenterol Hepatol* 2022;2022:6010367.
56. Li Y, Xing S, Chen R, et al. The effect of oral polyethylene glycol combined with simethicone for colonoscopy on cecal intubation rate, tolerability and acceptability: a systematic review and meta-analysis. *Acta Gastroenterol Belg* 2019;82:407-15.
57. ASGE Technology Committee; Trindade AJ, Lichtenstein DR, Aslanian HR, et al. Devices and methods to improve colonoscopy completion (with videos). *Gastrointest Endosc* 2018;87:625-34.
58. Rex DK, Repici A, Gross SA, et al. High-definition colonoscopy versus Endocuff versus EndoRings versus full-spectrum endoscopy for adenoma detection at colonoscopy: a multicenter randomized trial. *Gastrointest Endosc* 2018;88:335-44.
59. Rex DK, Lehman GA, Ulbright TM, et al. Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history. *Am J Gastroenterol* 1993;88:825-31.
60. Lieberman DA, Weiss DG, Bond JH, et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. *N Engl J Med* 2000;343:162-8.
61. Imperiale TF, Wagner DR, Lin CY, et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. *N Engl J Med* 2000;343:169-74.
62. Schoenfeld P, Cash B, Flood A, et al. Colonoscopic screening of average-risk women for colorectal neoplasia. *N Engl J Med* 2005;352:2061-8.
63. Patel SG, May FP, Anderson JC, et al. Updates on age to start and stop colorectal cancer screening: recommendations from the U.S. Multi-Society Task Force on Colorectal Cancer. *Gastrointest Endosc* 2022;95:1-15.
64. Karsenti D, Tharsis G, Burtin P, et al. Adenoma and advanced neoplasia detection rates increase from 45 years of age. *World J Gastroenterol* 2019;25:447-56.
65. Imperiale TF, Kisiel JB, Itzkowitz SH, et al. Specificity of the multi-target stool DNA test for colorectal cancer screening in average-risk 45-49 year-olds: a cross-sectional study. *Cancer Prev Res* 2021;14:489-96.
66. Butterly LF, Siegel RL, Fedewa S, et al. Colonoscopy outcomes in average-risk screening equivalent young adults: data from the New Hampshire Colonoscopy Registry. *Am J Gastroenterol* 2021;116:171-9.
67. Shaukat A, Rex DK, Shyne M, et al. Adenoma detection rates for 45- to 49-year-old screening population. *Gastroenterology* 2022;162:957-9.
68. Ladabaum U, Shepard J, Mannalithara A. Adenoma and sessile serrated lesion detection rates at screening colonoscopy for ages 45-49 years vs older ages since the introduction of new colorectal cancer screening guidelines. *Clin Gastroenterol Hepatol* 2022;20:2895-904.
69. Liang PS, Williams JL, Dominitz JA, et al. Age-stratified prevalence and predictors of neoplasia among U.S. adults undergoing screening colonoscopy in a national endoscopy registry. *Gastroenterology* 2022;163:742-53.
70. Bilal M, Holub J, Greenwald D, et al. Adenoma detection rates in 45-49-year-old persons undergoing screening colonoscopy: analysis from the GIQuIC registry. *Am J Gastroenterol* 2022;117:806-8.
71. Trivedi PD, Mohapatra A, Morris MK, et al. Prevalence and predictors of young-onset colorectal neoplasia: insights from a nationally representative colonoscopy registry. *Gastroenterology* 2022;162:1136-46.
72. Shaukat A, Holub J, Pike IM, et al. Benchmarking adenoma detection rates for colonoscopy: results from a US-based registry. *Am J Gastroenterol* 2021;116:1946-9.
73. Ross WA, Thirumurthi S, Lynch PM, et al. Detection rates of premalignant polyps during screening colonoscopy: time to revise quality standards? *Gastrointest Endosc* 2015;81:567-74.
74. Yang PF, Wong SW. Adenoma detection rate in colonoscopy: Is indication a predictor? *Surg Laparosc Endosc Percutan Tech* 2016;26:156-61.
75. Ponugoti PL, Rex DK. Yield of a second screening colonoscopy 10 years after an initial negative examination in average-risk individuals. *Gastrointest Endosc* 2017;85:221-4.
76. Rex DK, Ponugoti PL, Johnson CS, et al. Neoplasia at 10-year follow-up screening colonoscopy in a private U.S. practice: comparison of yield to first-time examinations. *Gastrointest Endosc* 2018;87:254-9.
77. Anderson JC, Butterly LF, Goodrich M, et al. Differences in detection rates of adenomas and serrated polyps in screening versus surveillance colonoscopies, based on the New Hampshire Colonoscopy Registry. *Clin Gastroenterol Hepatol* 2013;11:1308-12.
78. Marcondes FO, Dean KM, Schoen RE, et al. The impact of exclusion criteria on a physician's adenoma detection rate. *Gastrointest Endosc* 2015;82:668-75.
79. Boroff ES, Disbrow M, Crowell MD, et al. Adenoma and polyp detection rates in colonoscopy according to indication. *Gastroenterol Res Pract* 2017;2017:7207595.
80. Rex DK, Ponugoti PL. Calculating the adenoma detection rate in screening colonoscopies only: Is it necessary? Can it be gamed? *Endoscopy* 2017;49:1069-74.
81. Brand EC, Crook JE, Thomas CS, et al. Development and validation of a prediction model for adenoma detection during screening and surveillance colonoscopy with comparison to actual adenoma detection rates. *PLoS One* 2017;12:e0185560.
82. Kaltenbach T, Gawron A, Meyer CS, et al. Adenoma detection rate (ADR) irrespective of indication is comparable to screening ADR: implications for quality monitoring. *Clin Gastroenterol Hepatol* 2021;19:1883-9.
83. Desai M, Rex DK, Bohm ME, et al. Impact of withdrawal time on adenoma detection rate: results from a prospective multicenter trial. *Gastrointest Endosc* 2023;97:537-43.
84. Kajzrlíkova IM, Vitek P, Chalupa J, et al. Correlation between ADR of screening and all colonoscopies. *Biomed Papers Olom* 2021;165:386-9.
85. Wisse PHA, Erler NS, de Boer SY, et al. Adenoma detection rate and risk for interval postcolonoscopy colorectal cancer in fecal immunochemical test-based screening : a population-based cohort study. *Ann Intern Med* 2022;175:1366-73.
86. Cubiella J, Digby J, Rodriguez-Alonso L, et al. The fecal hemoglobin concentration, age and sex test score: development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients. *Int J Cancer* 2017;140:2201-11.
87. Anderson JC, Robinson CM, Hisey W, et al. Colonoscopy findings in FIT+ and mt-sDNA+ patients versus in colonoscopy-only patients: New Hampshire Colonoscopy Registry data. *Cancer Prev Res* 2022;15:455-64.
88. Hilsden RJ, Bridges R, Dube C, et al. Defining benchmarks for adenoma detection rate and adenomas per colonoscopy in patients undergoing colonoscopy due to a positive fecal immunochemical test. *Am J Gastroenterol* 2016;111:1743-9.

89. Kligman E, Li W, Eckert GJ, et al. Adenoma detection rate in asymptomatic patients with positive fecal immunochemical tests. *Dig Dis Sci* 2018;63:1167-72.
90. Robertson DJ, Lee JK, Boland CR, et al. Recommendations on fecal immunochemical testing to screen for colorectal neoplasia: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. *Gastroenterology* 2017;152:1217-37.
91. Corley DA, Jensen CD, Chubak J, et al. Evaluating different approaches for calculating adenoma detection rate: Is screening colonoscopy the gold standard? *Gastroenterology* 2023;165:784-7.
92. Schottinger JE, Jensen CD, Ghai NR, et al. Association of physician adenoma detection rates with postcolonoscopy colorectal cancer. *JAMA* 2022;327:2114-22.
93. Brenner H, Altenhofen L, Kretschmann J, et al. Trends in adenoma detection rates during the first 10 years of the German screening colonoscopy program. *Gastroenterology* 2015;149:356-66.
94. Hilsden RJ, Rose SM, Dube C, et al. Defining and applying locally relevant benchmarks for the adenoma detection rate. *Am J Gastroenterol* 2019;114:1315-21.
95. Rex DK, Sullivan AW, Perkins AJ, et al. Colorectal polyp prevalence and aspirational detection targets determined using high definition colonoscopy and a high level detector in 2017. *Dig Liver Dis* 2020;52:72-8.
96. Hassan C, Piovani D, Spadaccini M, et al. Variability in adenoma detection rate in control groups of randomized colonoscopy trials. *Gastrointest Endosc* 2022;97:212-25.
97. Do A, Weinberg J, Kakkar A, et al. Reliability of adenoma detection rate is based on procedural volume. *Gastrointest Endosc* 2013;77:376-80.
98. Selby K, Jensen CD, Levin TR, et al. Program components and results from an organized colorectal cancer screening program using annual fecal immunochemical testing. *Clin Gastroenterol Hepatol* 2022;20:145-52.
99. Mohan BP, Khan SR, Daugherty E, et al. Pooled rates of adenoma detection by colonoscopy in asymptomatic average-risk individuals with positive fecal immunochemical test: a systematic review and meta-analysis. *Gastrointest Endosc* 2022;96:208-22.
100. Johnson DH, Kisiel JB, Burger KN, et al. Multitarget stool DNA test: clinical performance and impact on yield and quality of colonoscopy for colorectal cancer screening. *Gastrointest Endosc* 2017;85:657-65.
101. Anderson JC, Robinson CM, Hisey WM, et al. Colorectal neoplasia detection in individuals with positive multitarget stool DNA tests: data from the New Hampshire Colonoscopy Registry. *J Clin Gastroenterol* 2022;56:419-25.
102. Eckmann JD, Ebner DW, Bering J, et al. Multitarget stool DNA screening in clinical practice: high positive predictive value for colorectal neoplasia regardless of exposure to previous colonoscopy. *Am J Gastroenterol* 2020;115:608-15.
103. Vakili N, Ciezki K, Huq N, et al. Multitarget stool DNA testing for the prevention of colon cancer: outcomes in a large integrated health-care system. *Gastrointest Endosc* 2020;92:334-41.
104. Rex DK, Alikhan M, Cummings O, et al. Accuracy of pathologic interpretation of colorectal polyps by general pathologists in community practice. *Gastrointest Endosc* 1999;50:468-74.
105. Rex DK. Detection measures for colonoscopy: considerations on the adenoma detection rate, recommended detection thresholds, withdrawal times, and potential updates to measures. *J Clin Gastroenterol* 2020;54:130-5.
106. Wieszczy P, Bugajski M, Januszewicz W, et al. Comparison of quality measures for detection of neoplasia at screening colonoscopy. *Clin Gastroenterol Hepatol* 2023;21:200-9.
107. Kahi CJ, Vemulapalli KC, Johnson CS, et al. Improving measurement of the adenoma detection rate and adenoma per colonoscopy quality metric: the Indiana University experience. *Gastrointest Endosc* 2014;79:448-54.
108. Gessi I, Waldmann E, Penz D, et al. Evaluation of adenomas per colonoscopy and adenomas per positive participant as new quality parameters in screening colonoscopy. *Gastrointest Endosc* 2019;89:496-502.
109. Wang S, Kim AS, Church TR, et al. Adenomas per colonoscopy and adenoma per positive participant as quality indicators for screening colonoscopy. *Endosc Int Open* 2020;8:E1560-5.
110. Park SK, Kim HY, Lee CK, et al. Comparison of adenoma detection rate and adenoma per colonoscopy as a quality indicator of colonoscopy. *Scand J Gastroenterol* 2016;51:886-90.
111. Wang HS, Pisegna J, Modi R, et al. Adenoma detection rate is necessary but insufficient for distinguishing high versus low endoscopist performance. *Gastrointest Endosc* 2013;77:71-8.
112. Han JH, Kim HG, Ahn EM, et al. Correlation between surrogate quality indicators for adenoma detection rate and adenoma miss rate in qualified colonoscopy, CORE study: KASID multicenter study. *Gut Liver* 2022;16:716-25.
113. Aziz M, Haghbin H, Sayeh W, et al. Comparison of artificial intelligence with other interventions to improve adenoma detection rate for colonoscopy: a network meta-analysis. *J Clin Gastroenterol* 2022;58:143-55.
114. Rex DK, Hardacker K, MacPhail M, et al. Determining the adenoma detection rate and adenomas per colonoscopy by photography alone: proof-of-concept study. *Endoscopy* 2015;47:245-50.
115. Peng M, Rex DK. Surveying ADR knowledge and practices among US gastroenterologists. *J Clin Gastroenterol* 2020;54:158-63.
116. Khalid O, Radaideh S, Cummings OW, et al. Reinterpretation of histology of proximal colon polyps called hyperplastic in 2001. *World J Gastroenterol* 2009;15:3767-70.
117. Payne SR, Church TR, Wandell M, et al. Endoscopic detection of proximal serrated lesions and pathologic identification of sessile serrated adenomas/polyps vary on the basis of center. *Clin Gastroenterol Hepatol* 2014;12:1119-26.
118. Vennelaganti S, Cuatrecasas M, Vennelaganti P, et al. Moderate inter-observer agreement among pathologists in differentiation of sessile serrated from hyperplastic polyps. *Gastroenterology* 2020;160:452-4.
119. Gourevitch RA, Rose S, Crockett SD, et al. Variation in pathologist classification of colorectal adenomas and serrated polyps. *Am J Gastroenterol* 2018;113:431-9.
120. Rex DK, Ahnen DJ, Baron JA, et al. Serrated lesions of the colorectum: review and recommendations from an expert panel. *Am J Gastroenterol* 2012;107:1315-29; quiz 1314, 30.
121. Anderson JC, Hisey W, Mackenzie TA, et al. Clinically significant serrated polyp detection rates and risk for post colonoscopy colorectal cancer: data from the New Hampshire Colonoscopy Registry. *Gastrointest Endosc* 2022;96:310-7.
122. van Toledo D, JEG IJ, Bossuyt PMM, et al. Serrated polyp detection and risk of interval post-colonoscopy colorectal cancer: a population-based study. *Lancet Gastroenterol Hepatol* 2022;7:747-54.
123. Zessner-Spitzenberg J, Waldmann E, Jiricka L, et al. Comparison of adenoma detection rate and proximal serrated polyp detection rate and their effect on post-colonoscopy colorectal cancer mortality in screening patients. *Endoscopy* 2022;55:434-41.
124. Shaukat A, Holub J, Greenwald D, et al. Variation over time and factors associated with detection rates of sessile serrated lesion across the United States: results from a national sample using the GIQuC Registry. *Am J Gastroenterol* 2021;116:95-9.
125. Je IJ, Madani A, Overbeek LI, et al. Implementation of an e-learning module improves consistency in the histopathological diagnosis of sessile serrated lesions within a nationwide population screening programme. *Histopathology* 2017;70:929-37.
126. Desai M, Anderson JC, Kaminski M, et al. Sessile serrated lesion detection rates during average risk screening colonoscopy: a systematic review and meta-analysis of the published literature. *Endosc Int Open* 2021;9:E610-20.

127. Meester RGS, van Herk M, Lansdorp-Vogelaar I, et al. Prevalence and clinical features of sessile serrated polyps: a systematic review. *Gastroenterology* 2020;159:105-18.
128. Anderson JC, Rex DK, Mackenzie TA, et al. Higher serrated polyp detection rates are associated with lower risk for post colonoscopy colorectal cancer: data from the New Hampshire Colonoscopy Registry. *Am J Gastroenterol* 2023;118:1927-30.
129. Chang LC, Shun CT, Hsu WF, et al. Fecal immunochemical test detects sessile serrated adenomas and polyps with a low level of sensitivity. *Clin Gastroenterol Hepatol* 2017;15:872-9.
130. Anderson JC, Hisey WM, Robinson CM, et al. Serrated polyp yield at colonoscopy in patients with positive FIT, positive mt-sDNA, and colonoscopy only: Data from the New Hampshire Colonoscopy Registry. *Cancer Epidemiol Biomark Prev* 2023;32:226-32.
131. Rex DK, Cutler CS, Lemmel GT, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. *Gastroenterology* 1997;112:24-8.
132. Barclay RL, Vicari JJ, Greenlaw RL. Effect of a time-dependent colonoscopic withdrawal protocol on adenoma detection during screening colonoscopy. *Clin Gastroenterol Hepatol* 2008;6:1091-8.
133. Overholt BF, Brooks-Belli L, Grace M, et al. Withdrawal times and associated factors in colonoscopy: a quality assurance multicenter assessment. *J Clin Gastroenterol* 2010;44:e80-6.
134. Benson ME, Reichelderfer M, Said A, et al. Variation in colonoscopic technique and adenoma detection rates at an academic gastroenterology unit. *Dig Dis Sci* 2010;55:166-71.
135. Liang J, Kalady MF, Appau K, et al. Serrated polyp detection rate during screening colonoscopy. *Colorectal Dis* 2012;14:1323-7.
136. Jover R, Zapater P, Polania E, et al. Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. *Gastrointest Endosc* 2013;77:381-9.
137. Lee TJ, Blanks RG, Rees CJ, et al. Longer mean colonoscopy withdrawal time is associated with increased adenoma detection: evidence from the Bowel Cancer Screening Programme in England. *Endoscopy* 2013;45:20-6.
138. Butterly L, Robinson CM, Anderson JC, et al. Serrated and adenomatous polyp detection increases with longer withdrawal time: results from the New Hampshire Colonoscopy Registry. *Am J Gastroenterol* 2014;109:417-26.
139. Kashiwagi K, Inoue N, Yoshida T, et al. Polyp detection rate in transverse and sigmoid colon significantly increases with longer withdrawal time during screening colonoscopy. *PLoS One* 2017;12:e0174155.
140. Coghlan E, LaFerrere L, Zenon E, et al. Timed screening colonoscopy: a randomized trial of two colonoscopic withdrawal techniques. *Surg Endosc* 2020;34:1200-5.
141. Yun GY, Eun HS, Kim JS, et al. Colonoscopic withdrawal time and adenoma detection in the right colon. *Medicine* 2018;97:e12113.
142. Patel VD, Thompson WK, Lapin BR, et al. Screening colonoscopy withdrawal time threshold for adequate proximal serrated polyp detection rate. *Dig Dis Sci* 2018;63:3084-90.
143. Cavicchi M, Tharsis G, Burtin P, et al. Difference in physician- and patient-dependent factors contributing to adenoma detection rate and serrated polyp detection rate. *Dig Dis Sci* 2019;64:3579-88.
144. Jung Y, Joo YE, Kim HG, et al. Relationship between the endoscopic withdrawal time and adenoma/polyp detection rate in individual colonic segments: a KASID multicenter study. *Gastrointest Endosc* 2019;89:523-30.
145. Zhao S, Yang X, Wang S, et al. Impact of 9-minute withdrawal time on the adenoma detection rate: a multicenter randomized controlled trial. *Clin Gastroenterol Hepatol* 2022;20:e168-81.
146. Zhao S, Song Y, Wang S, et al. Reduced adenoma miss rate with 9-minute vs. 6-minute withdrawal times for screening colonoscopy: a multicenter randomized tandem trial: nine-minute WT reduces the AMR of screening colonoscopy. *Am J Gastroenterol* 2022;118:802-11.
147. Shaukat A, Rector TS, Church TR, et al. Longer withdrawal time is associated with a reduced incidence of interval cancer after screening colonoscopy. *Gastroenterology* 2015;149:952-7.
148. Rex DK. Colonoscopic withdrawal technique is associated with adenoma miss rates. *Gastrointest Endosc* 2000;51:33-6.
149. Rex DK, Hewett DG, Raghavendra M, et al. The impact of videorecording on the quality of colonoscopy performance: a pilot study. *Am J Gastroenterol* 2010;105:2312-7.
150. Rex DK, Slaven JE, Garcia J, et al. Endocuff Vision reduces inspection time without decreasing lesion detection: a clinical randomized trial. *Clin Gastroenterol Hepatol* 2020;18:158-62.
151. Kaltenbach T, Anderson JC, Burke CA, et al. Endoscopic removal of colorectal lesions-recommendations by the US Multi-Society Task Force on Colorectal Cancer. *Gastrointest Endosc* 2020;91:486-519.
152. Ferlitsch M, Moss A, Hassan C, et al. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) clinical guideline. *Endoscopy* 2017;49:270-97.
153. Plumb AA, Nickerson C, Wooldrage K, et al. Terminal digit preference biases polyp size measurements at endoscopy, computed tomographic colonography, and histopathology. *Endoscopy* 2016;48:899-908.
154. The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. *Gastrointest Endosc* 2003;58:S3-43.
155. Shaukat A, Kaltenbach T, Dominitz JA, et al. Endoscopic recognition and management strategies for malignant colorectal polyps: recommendations of the US Multi-Society Task Force on Colorectal Cancer. *Gastrointest Endosc* 2020;92:997-1015.
156. van Doorn SC, Hazewinkel Y, East JE, et al. Polyp morphology: an interobserver evaluation for the Paris classification among international experts. *Am J Gastroenterol* 2015;110:180-7.
157. Suresh S, Zhang J, Ahmed A, et al. Risk factors associated with adenoma recurrence following cold snare endoscopic mucosal resection of polyps \geq 20 mm: a retrospective chart review. *Endosc Int Open* 2021;9:E867-73.
158. Sreepati G, Vemulapalli KC, Rex DK. Clip artifact after closure of large colorectal EMR sites: incidence and recognition. *Gastrointest Endosc* 2015;82:344-9.
159. Rex DK. Diagnosis and management of clip artifact on endoscopic mucosal resection scars. *Gastroenterol Hepatol* 2021;17:464-8.
160. Ponugoti PL, Cummings OW, Rex DK. Risk of cancer in small and diminutive colorectal polyps. *Dig Liver Dis* 2017;49:34-7.
161. Yamashina T, Fukuhara M, Maruo T, et al. Cold snare polypectomy reduced delayed postpolypectomy bleeding compared with conventional hot polypectomy: a propensity score-matching analysis. *Endosc Int Open* 2017;05:E587-94.
162. Paspatis GA, Tribonias G, Konstantinidis K, et al. A prospective randomized comparison of cold vs hot snare polypectomy in the occurrence of postpolypectomy bleeding in small colonic polyps. *Colorectal Dis* 2011;13:e345-8.
163. Trivedi M, Klapheke R, Youssef F, et al. Comparison of cold snare and hot snare polypectomy for the resection of sporadic nonampullary duodenal adenomas. *Gastrointest Endosc* 2022;96:657-64.
164. Takamaru H, Saito Y, Hammoud GM, et al. Comparison of postpolypectomy bleeding events between cold snare polypectomy and hot snare polypectomy for small colorectal lesions: a large-scale propensity score-matched analysis. *Gastrointest Endosc* 2021;95:982-9.
165. Toyosawa J, Yamasaki Y, Fujimoto T, et al. Resection depth for small colorectal polyps comparing cold snare polypectomy, hot snare polypectomy and underwater endoscopic mucosal resection. *Endosc Int Open* 2022;10:E602-8.
166. Suzuki S, Gotoda T, Kusano C, et al. Width and depth of resection for small colorectal polyps: hot versus cold snare polypectomy. *Gastrointest Endosc* 2018;87:1095-103.

167. Pedersen IB, Rawa-Golebiewska A, Calderwood AH, et al. Complete polyp resection with cold snare versus hot snare polypectomy for polyps of 4-9 mm: a randomized controlled trial. *Endoscopy* 2022;54:961-9.
168. de Benito Sanz M, Hernandez L, Garcia Martinez MI, et al. Efficacy and safety of cold versus hot snare polypectomy for small (5-9 mm) colorectal polyps: a multicenter randomized controlled trial. *Endoscopy* 2022;54:35-44.
169. McCarty TR, Aihara H. Cold snare polypectomy should be preferred strategy for small, nonpedunculated colon polyps: results from a recent multicenter noninferiority randomized trial. *Gastrointest Endosc* 2022;96:339-40.
170. Varytimidiadis L, Viazis N, Gkolfakis P, et al. Cold snare polypectomy vs. hot snare polypectomy vs. argon plasma coagulation for small (5-9mm) left-sided colorectal polyps: a prospective randomized trial. *Eur J Gastroenterol Hepatol* 2021;33:e909-15.
171. Oh CK, Choi HS, Cho YS. Comparison of cold snare polypectomy and endoscopic mucosal resection for 3-10-mm colorectal polyps in end-stage renal disease patients. *Saudi J Gastroenterol* 2022;28: 67-73.
172. Kawamura T, Takeuchi Y, Asai S, et al. A comparison of the resection rate for cold and hot snare polypectomy for 4-9 mm colorectal polyps: a multicentre randomised controlled trial (CRESCENT study). *Gut* 2018;67:1950-7.
173. Rex DK, Anderson JC, Pohl H, et al. Cold versus hot snare resection with or without submucosal injection of 6- to 15-mm colorectal polyps: a randomized controlled trial. *Gastrointest Endosc* 2022;96: 330-8.
174. Shinozaki S, Kobayashi Y, Hayashi Y, et al. Efficacy and safety of cold versus hot snare polypectomy for resecting small colorectal polyps: systematic review and meta-analysis. *Dig Endosc* 2018;30:592-9.
175. Sidhu M, Forbes N, Tate DJ, et al. A randomized controlled trial of cold snare polypectomy technique: technique matters more than snare wire diameter. *Am J Gastroenterol* 2022;117:100.
176. Wei MT, Louie CY, Chen Y, et al. Randomized controlled trial investigating cold snare and forceps polypectomy among small POLYPs in rates of complete resection: the TINYPOLYP Trial. *Am J Gastroenterol* 2022;117:1305-10.
177. Perrod G, Perez-Cuadrado-Robles E, Coron E, et al. Comparison of cold biopsy forceps vs cold snare for diminutive colorectal polyp removal: a multicenter non-inferiority randomized controlled trial. *Clin Res Hepatol Gastroenterol* 2022;46:101867.
178. Desai S, Gupta S, Copur-Dahi N, et al. A prospective randomized study comparing jumbo biopsy forceps to cold snare for the resection of diminutive colorectal polyps. *Surg Endosc* 2020;34:1206-13.
179. Kim JS, Lee BI, Choi H, et al. Cold snare polypectomy versus cold forceps polypectomy for diminutive and small colorectal polyps: a randomized controlled trial. *Gastrointest Endosc* 2015;81:741-7.
180. Park SK, Ko BM, Han JP, et al. A prospective randomized comparative study of cold forceps polypectomy by using narrow-band imaging endoscopy versus cold snare polypectomy in patients with diminutive colorectal polyps. *Gastrointest Endosc* 2016;83:527-32.
181. Raad D, Tripathi P, Cooper G, et al. Role of the cold biopsy technique in diminutive and small colonic polyp removal: a systematic review and meta-analysis. *Gastrointest Endosc* 2016;83:508-15.
182. Jung YS, Park CH, Nam E, et al. Comparative efficacy of cold polypectomy techniques for diminutive colorectal polyps: a systematic review and network meta-analysis. *Surg Endosc* 2018;32:1149-59.
183. Kudo T, Horiuchi A, Horiuchi I, et al. Pedunculated colorectal polyps with heads \leq 1 cm in diameter can be resected using cold snare polypectomy. *Acta Gastroenterol Belg* 2021;84:411-5.
184. Arimoto J, Chiba H, Ashikari K, et al. Management of less than 10-mm-sized pedunculated (lp) polyps with thin stalk: hot snare polypectomy versus cold snare polypectomy. *Dig Dis Sci* 2021;66:2353-61.
185. Pohl H, de Latour R, Reuben A, et al. GI multisociety strategic plan on environmental sustainability. *Gastroenterology* 2022;163:1695-701.
186. Pohl H, Robertson DJ. Colorectal cancers detected after colonoscopy frequently result from missed lesions. *Clin Gastroenterol Hepatol* 2010;8:858-64.
187. Beaton D, Beintaris I, Rutter MD. Utilization and reproducibility of World Endoscopy Organization post-colonoscopy colorectal cancer algorithms: retrospective analysis. *Endoscopy* 2022;54:270-7.
188. Anderson R, Burr NE, Valori R. Causes of post-colonoscopy colorectal cancers based on world endoscopy organization system of analysis. *Gastroenterology* 2020;158:1287-99.
189. Pohl H, Srivastava A, Bensen SP, et al. Incomplete polyp resection during colonoscopy-results of the complete adenoma resection (CARE) study. *Gastroenterology* 2013;144:74-80.
190. Gupta S, Anderson J, Bhandari P, et al. Development and validation of a novel method for assessing competency in polypectomy: direct observation of polypectomy skills. *Gastrointest Endosc* 2011;73: 1232-9.
191. Patel SG, Duloy A, Kaltenbach T, et al. Development and validation of a video-based cold snare polypectomy assessment tool (with videos). *Gastrointest Endosc* 2019;89:1222-30.
192. Jayanna M, Burgess NG, Singh R, et al. Cost analysis of endoscopic mucosal resection vs surgery for large laterally spreading colorectal lesions. *Clin Gastroenterol Hepatol* 2016;14:271-8.
193. Keswani RN, Law R, Ciolino JD, et al. Adverse events after surgery for nonmalignant colon polyps are common and associated with increased length of stay and costs. *Gastrointest Endosc* 2016;84: 296-303.
194. Saade R, Tsang T, Kmeid M, et al. Overutilization of surgical resection for benign colorectal polyps: analysis from a tertiary care center. *Endosc Int Open* 2021;9:E706-12.
195. Stockley C, Evans B, Loughheed M, et al. Management of the colonic polyps referred for surgery: an opportunity for improvement. *Surg Endosc* 2022;36:5392-7.
196. Wickham CJ, Wang J, Mirza KL, et al. "Unresectable" polyp management utilizing advanced endoscopic techniques results in high rate of colon preservation. *Surg Endosc* 2022;36:2121-8.
197. Fraiman J, Brownlee S, Stoto MA, et al. An estimate of the US rate of overuse of screening colonoscopy: a systematic review. *J Gen Intern Med* 2022;37:1754-62.
198. Mysliwiec PA, Brown ML, Klabunde CN, et al. Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. *Ann Intern Med* 2004;141:264-71.
199. Laiyemo AO, Pinsky PF, Marcus PM, et al. Utilization and yield of surveillance colonoscopy in the continued follow-up study of the polyp prevention trial. *Clin Gastroenterol Hepatol* 2009;7:562-7; quiz 497.
200. Schoen RE, Pinsky PF, Weissfeld JL, et al. Utilization of surveillance colonoscopy in community practice. *Gastroenterology* 2010;138:73-81.
201. Anderson JC, Baron JA, Ahnen DJ, et al. Factors associated with shorter colonoscopy surveillance intervals for patients with low-risk colorectal adenomas and effects on outcome. *Gastroenterology* 2017;152:1933-43.
202. Dong J, Wang LF, Ardolino E, et al. Real-world adherence to the 2020 United States Multi-Society Task Force polypectomy surveillance guidelines: an observational study. *Gastrointest Endosc* 2022;97: 350-6.
203. Saini SD, Nayak RS, Kuhn L, et al. Why don't gastroenterologists follow colon polyp surveillance guidelines? Results of a national survey. *J Clin Gastroenterol* 2009;43:554-8.
204. Kim ER, Sinn DH, Kim JY, et al. Factors associated with adherence to the recommended postpolypectomy surveillance interval. *Surg Endosc* 2012;26:1690-5.
205. Patel N, Tong L, Ahn C, et al. Post-polypectomy guideline adherence: importance of belief in guidelines, not guideline knowledge or fear of missed cancer. *Dig Dis Sci* 2015;60:2937-45.
206. Desai V, Sussman DA, Greenspan M, et al. Most premature surveillance colonoscopy is not attributable to bowel preparation or new clinical indications. *Dig Dis Sci* 2016;61:2496-504.

207. Calderwood AH, Tosteson TD, Walter LC, et al. Colonoscopy utilization and outcomes in older adults: Data from the New Hampshire Colonoscopy Registry. *J Am Geriatr Soc* 2022;70:801-11.
208. Meester RGS, Lansdorp-Vogelaar I, Winawer SJ, et al. High-intensity versus low-intensity surveillance for patients with colorectal adenomas: a cost-effectiveness analysis. *Ann Intern Med* 2019;171:612-22.
209. Rutter MD, East J, Rees CJ, et al. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines. *Gut* 2020;69:201-23.
210. Hassan C, Antonelli G, Dumonceau JM, et al. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) guideline— update 2020. *Endoscopy* 2020;52:687-700.
211. Magrath M, Yang E, Ahn C, et al. Impact of a clinical decision support system on guideline adherence of surveillance recommendations for colonoscopy after polypectomy. *J Natl Compr Canc Netw* 2018;16:1321-8.
212. Shafer LA, Restall G, Simms A, et al. Clinician based decision tool to guide recommended interval between colonoscopies: development and evaluation pilot study. *BMC Med Inform Decis Mak* 2022;22:136.
213. Kothari ST, Huang RJ, Shaikat A, et al. ASGE review of adverse events in colonoscopy. *Gastrointest Endosc* 2019;90:863-76.
214. Stock C, Ihle P, Sieg A, et al. Adverse events requiring hospitalization within 30 days after outpatient screening and nonscreening colonoscopies. *Gastrointest Endosc* 2013;77:419-29.
215. Rutter CM, Johnson E, Miglioretti DL, et al. Adverse events after screening and follow-up colonoscopy. *Cancer Causes Control* 2012;23:289-96.
216. Ladabaum U, Mannalithara A, Desai M, et al. Age-specific rates and time-courses of gastrointestinal and nongastrointestinal complications associated with screening/surveillance colonoscopy. *Am J Gastroenterol* 2021;116:2430-45.
217. Accreditation standards for elements of performance. The Joint Commission 2023. Available at: https://www.jointcommission.org/what-we-offer/accreditation/health-care-settings/assisted-living-community/prepare/survey-preparation-resources?utm_campaign=TJC2209_ALC_cpc&utm_source=google&utm_medium=cpc&gad_source=1&gclid=EAlalQobChMlp-C9l6S9hgMVfjclBR3OhAiuEAAAYASAAEgJa_fD_BwE. Accessed June 2, 2024.
218. Carrico R, Ramirez J. A process for analysis of sentinel events due to health care-associated infection. *Am J Infect Control* 2007;35:501-7.
219. Bagian JP, Gosbee J, Lee CZ, et al. The Veterans Affairs root cause analysis system in action. *Jt Comm J Qual Improv* 2002;28:531-45.
220. Wood LJ, Wiegmann DA. Beyond the corrective action hierarchy: a systems approach to organizational change. *Int J Qual Health Care* 2020;32:438-44.
221. Patra KP, De Jesus O. Sentinel event. In: *StatPearls* [Internet]. Treasure Island, Florida: StatPearls Publishing; Jan 2024.
222. de'Angelis N, Di Saverio S, Chiara O, et al. 2017 WSES guidelines for the management of iatrogenic colonoscopy perforation. *World J Emerg Surg* 2018;13:5.
223. Fruhmorgen P, Demling L. Complications of diagnostic and therapeutic colonoscopy in the Federal Republic of Germany. Results of an inquiry. *Endoscopy* 1979;11:146-50.
224. Silvis SE, Nebel O, Rogers G, et al. Endoscopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy survey. *JAMA* 1976;235:928-30.
225. Lee JS, Kim JY, Kang BM, et al. Clinical outcomes of laparoscopic versus open surgery for repairing colonoscopic perforation: a multicenter study. *Surg Today* 2021;51:285-92.
226. Iqbal CW, Cullinane DC, Schiller HJ, et al. Surgical management and outcomes of 165 colonoscopic perforations from a single institution. *Arch Surg* 2008;143:701-6; discussion 706-7.
227. Iqbal CW, Chun YS, Farley DR. Colonoscopic perforations: a retrospective review. *J Gastrointest Surg* 2005;9:1229-35; discussion 1236.
228. Anderson ML, Pasha TM, Leighton JA. Endoscopic perforation of the colon: lessons from a 10-year study. *Am J Gastroenterol* 2000;95:3418-22.
229. Rai V, Mishra N. Colonoscopic perforations. *Clin Colon Rectal Surg* 2018;31:41-6.
230. Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: Updated evidence report and systematic review for the U.S. Preventive Services Task Force. *JAMA* 2016;315:2576-94.
231. Reumkens A, Rondagh EJ, Bakker CM, et al. Post-colonoscopy complications: a systematic review, time trends, and meta-analysis of population-based studies. *Am J Gastroenterol* 2016;111:1092-101.
232. Warren JL, Klabunde CN, Mariotto AB, et al. Adverse events after outpatient colonoscopy in the Medicare population. *Ann Intern Med* 2009;150:849-57.
233. Mukewar S, Costedio M, Wu X, et al. Severe adverse outcomes of endoscopic perforations in patients with and without IBD. *Inflamm Bowel Dis* 2014;20:2056-66.
234. Lohsiriwat V. Colonoscopic perforation: incidence, risk factors, management and outcome. *World J Gastroenterol* 2010;16:425-30.
235. Bielawska B, Day AG, Lieberman DA, et al. Risk factors for early colonoscopic perforation include non-gastroenterologist endoscopists: a multivariable analysis. *Clin Gastroenterol Hepatol* 2014;12:85-92.
236. Ranasinghe I, Parzynski CS, Searfoss R, et al. Differences in colonoscopy quality among facilities: development of a post-colonoscopy risk-standardized rate of unplanned hospital visits. *Gastroenterology* 2016;150:103-13.
237. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. *Gastroenterology* 2008;135:1899-906.
238. Rex DK. Best practices for resection of diminutive and small polyps in the colorectum. *Gastrointest Endosc Clin North Am* 2019;29:603-12.
239. Repici A, Hassan C, Vitetta E, et al. Safety of cold polypectomy for <10mm polyps at colonoscopy: a prospective multicenter study. *Endoscopy* 2012;44:27-31.
240. Uno Y, Obara K, Zheng P, et al. Cold snare excision is a safe method for diminutive colorectal polyps. *Tohoku J Exp Med* 1997;183:243-9.
241. Memon MA, Memon B, Yunus RM, et al. Carbon dioxide versus air insufflation for elective colonoscopy: a meta-analysis and systematic review of randomized controlled trials. *Surg Laparosc Endosc Percutan Tech* 2016;26:102-16.
242. Yuan X, Gao H, Liu C, et al. Effectiveness and safety of the different endoscopic resection methods for 10- to 20-mm nonpedunculated colorectal polyps: a systematic review and pooled analysis. *Saudi J Gastroenterol* 2021;27:331-41.
243. Cho SB, Lee WS, Joo YE, et al. Therapeutic options for iatrogenic colon perforation: feasibility of endoscopic clip closure and predictors of the need for early surgery. *Surg Endosc* 2012;26:473-9.
244. Baron TH, Song LM, Ross A, et al. Use of an over-the-scope clipping device: multicenter retrospective results of the first U.S. experience (with videos). *Gastrointest Endosc* 2012;76:202-8.
245. Nivatvongs S. Complications in colonoscopic polypectomy—an experience with 1555 polypectomies. *Dis Colon Rectum* 1986;29:825-30.
246. Zubarik R, Fleischer DE, Mastropietro C, et al. Prospective analysis of complications 30 days after outpatient colonoscopy. *Gastrointest Endosc* 1999;50:322-8.
247. Khashab M, Eid E, Rusche M, et al. Incidence and predictors of "late" recurrences after endoscopic piecemeal resection of large sessile adenomas. *Gastrointest Endosc* 2009;70:344-9.
248. Buchner AM, Guarner-Argente C, Ginsberg GG. Outcomes of EMR of defiant colorectal lesions directed to an endoscopy referral center. *Gastrointest Endosc* 2012;76:255-63.
249. Singh M, Mehta N, Murthy UK, et al. Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy. *Gastrointest Endosc* 2010;71:998-1005.
250. Witt DM, Delate T, McCool KH, et al. Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and

- not receiving anticoagulation therapy. *J Thromb Haemost* 2009;7:1982-9.
251. Kim HS, Kim TI, Kim WH, et al. Risk factors for immediate postpolypectomy bleeding of the colon: a multicenter study. *Am J Gastroenterol* 2006;101:1333-41.
 252. Buddingh KT, Herngreen T, Haringsma J, et al. Location in the right hemi-colon is an independent risk factor for delayed postpolypectomy hemorrhage: a multi-center case-control study. *Am J Gastroenterol* 2011;106:1119-24.
 253. Kim JH, Lee HJ, Ahn JW, et al. Risk factors for delayed postpolypectomy hemorrhage: a case-control study. *J Gastroenterol Hepatol* 2013;28:645-9.
 254. Consolo P, Luigiano C, Strangio G, et al. Efficacy, risk factors and complications of endoscopic polypectomy: ten year experience at a single center. *World J Gastroenterol* 2008;14:2364-9.
 255. Parra-Blanco A, Kaminaga N, Kojima T, et al. Colonoscopic polypectomy with cutting current: is it safe? *Gastrointest Endosc* 2000;51:676-81.
 256. Van Gossom A, Cozzoli A, Adler M, et al. Colonoscopic snare polypectomy: analysis of 1485 resections comparing two types of current. *Gastrointest Endosc* 1992;38:472-5.
 257. Pohl H, Grimm IS, Moyer MT, et al. Effects of blended (yellow) vs forced coagulation (blue) currents on adverse events, complete resection, or polyp recurrence after polypectomy in a large randomized trial. *Gastroenterology* 2020;159:119-28.
 258. ASGE Standards of Practice Committee; Acosta RD, Abraham NS, Chandraskhara V, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. *Gastrointest Endosc* 2016;83:3-16.
 259. Telford JJ, Abraham NS. Management of antiplatelet and anticoagulant agents before and after polypectomy. *Gastrointest Endosc Clin North Am* 2022;32:299-312.
 260. Chang LC, Chang CY, Chen CY, et al. Cold versus hot snare polypectomy for small colorectal polyps: a pragmatic randomized controlled trial. *Ann Intern Med* 2023;176:311-9.
 261. Di Giorgio P, De Luca L, Calcagno G, et al. Detachable snare versus epinephrine injection in the prevention of postpolypectomy bleeding: a randomized and controlled study. *Endoscopy* 2004;36:860-3.
 262. Spadaccini M, Albeniz E, Pohl H, et al. Prophylactic clipping after colorectal endoscopic resection prevents bleeding of large, proximal polyps: meta-analysis of randomized trials. *Gastroenterology* 2020;159:148-58.
 263. Rex DK, Lewis BS, Wayne JD. Colonoscopy and endoscopic therapy for delayed post-polypectomy hemorrhage. *Gastrointest Endosc* 1992;38:127-9.
 264. Guo XF, Yu XA, Hu JC, et al. Endoscopic management of delayed bleeding after polypectomy of small colorectal polyps: two or more clips may be safe. *Gastroenterol Rep* 2022;10:goab051.
 265. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG clinical guideline: ulcerative colitis in adults. *Am J Gastroenterol* 2019;114:384-413.
 266. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut* 2006;55:749-53.
 267. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. *Gastroenterology* 2021;160:1570-83.
 268. Shah SC, Colombel JF, Sands BE, et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2016;14:1245-55.
 269. Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). *Gastrointest Endosc* 2020;91:733-45.
 270. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. *N Engl J Med* 1987;317:1625-9.
 271. Lobaton T, Bessissow T, De Hertogh G, et al. The Modified Mayo Endoscopic Score (MMES): a new index for the assessment of extension and severity of endoscopic activity in ulcerative colitis patients. *J Crohns Colitis* 2015;9:846-52.
 272. Travis SP, Schnell D, Krzeski P, et al. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). *Gut* 2012;61:535-42.
 273. Ikeya K, Hanai H, Sugimoto K, et al. The Ulcerative Colitis Endoscopic Index of Severity more accurately reflects clinical outcomes and long-term prognosis than the Mayo Endoscopic Score. *J Crohns Colitis* 2016;10:286-95.
 274. Samuel S, Bruining DH, Loftus EV Jr, et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. *Clin Gastroenterol Hepatol* 2013;11:49-54.
 275. Iacucci M, Smith SCL, Bazarova A, et al. An international multicenter real-life prospective study of electronic chromoendoscopy score PI-CaSSO in ulcerative colitis. *Gastroenterology* 2021;160:1558-69.
 276. Daperno M, Comberlato M, Bossa F, et al. Training programs on endoscopic scoring systems for inflammatory bowel disease lead to a significant increase in interobserver agreement among community gastroenterologists. *J Crohns Colitis* 2017;11:556-61.
 277. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). *Gut* 1989;30:983-9.
 278. Khanna R, Zou G, D'Haens G, et al. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. *Gut* 2016;65:1119-25.
 279. Khanna R, Zou G, Stitt L, et al. Responsiveness of endoscopic indices of disease activity for Crohn's disease. *Am J Gastroenterol* 2017;112:1584-92.
 280. Daperno M, D'Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. *Gastrointest Endosc* 2004;60:505-12.
 281. Daperno M, Comberlato M, Bossa F, et al. Inter-observer agreement in endoscopic scoring systems: preliminary report of an ongoing study from the Italian Group for Inflammatory Bowel Disease (IG-IBD). *Dig Liver Dis* 2014;46:969-73.
 282. Sipponen T, Nuutinen H, Turunen U, et al. Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD. *Inflamm Bowel Dis* 2010;16:2131-6.
 283. Devlin SM, Melmed GY, Irving PM, et al. Recommendations for quality colonoscopy reporting for patients with inflammatory bowel disease: results from a RAND appropriateness panel. *Inflamm Bowel Dis* 2016;22:1418-24.
 284. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target. *Am J Gastroenterol* 2015;110:1324-38.
 285. Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the post-operative course of Crohn's disease. *Gastroenterology* 1990;99:956-63.
 286. Gordon H, Biancone L, Fiorino G, et al. ECCO guidelines on inflammatory bowel disease and malignancies. *J Crohns Colitis* 2022;17:827-54.
 287. Birch RJ, Burr N, Subramanian V, et al. Inflammatory bowel disease-associated colorectal cancer epidemiology and outcomes: an English population-based study. *Am J Gastroenterol* 2022;117:1858-70.
 288. Bogach J, Pond G, Eskicioglu C, et al. Age-related survival differences in patients with inflammatory bowel disease-associated colorectal cancer: a population-based cohort study. *Inflamm Bowel Dis* 2019;25:1957-65.
 289. Murthy SK, Feuerstein JD, Nguyen GC, et al. AGA clinical practice update on endoscopic surveillance and management of colorectal

- dysplasia in inflammatory bowel diseases: expert review. *Gastroenterology* 2021;161:1043-51.
290. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. *Gut* 2019;68:s1-106.
 291. Bye WA, Ma C, Nguyen TM, et al. Strategies for detecting colorectal cancer in patients with inflammatory bowel disease: a Cochrane systematic review and meta-analysis. *Am J Gastroenterol* 2018;113:1801-9.
 292. Rabbenou W, Ullman TA. Risk of colon cancer and recommended surveillance strategies in patients with ulcerative colitis. *Gastroenterol Clin North Am* 2020;49:791-807.
 293. Shaukat A, Tuskey A, Rao VL, et al. Interventions to improve adenoma detection rates for colonoscopy. *Gastrointest Endosc* 2022;96:171-83.
 294. Komanduri S, Dominitz JA, Rabeneck L, et al. AGA White Paper: challenges and gaps in innovation for the performance of colonoscopy for screening and surveillance of colorectal cancer. *Clin Gastroenterol Hepatol* 2022;20:2198-209.
 295. Lam AY, Duloy AM, Keswani RN. Quality indicators for the detection and removal of colorectal polyps and interventions to improve them. *Gastrointest Endosc Clin North Am* 2022;32:329-49.
 296. Gubbiotti A, Spadaccini M, Badalamenti M, et al. Key factors for improving adenoma detection rate. *Expert Rev Gastroenterol Hepatol* 2022;16:819-33.
 297. Keswani RN, Crockett SD, Calderwood AH. AGA clinical practice update on strategies to improve quality of screening and surveillance colonoscopy: expert review. *Gastroenterology* 2021;161:701-11.
 298. May FP, Shaukat A. State of the science on quality indicators for colonoscopy and how to achieve them. *Am J Gastroenterol* 2020;115:1183-90.
 299. Kaminski MF, Wieszczy P, Rupinski M, et al. Increased rate of adenoma detection associates with reduced risk of colorectal cancer and death. *Gastroenterology* 2017;153:98-105.
 300. Toyoshima O, Yoshida S, Nishizawa T, et al. Simple feedback of colonoscopy performance improved the number of adenomas per colonoscopy and serrated polyp detection rate. *Endosc Int Open* 2021;9:E1032-8.
 301. Boregowda U, Desai M, Nutalapati V, et al. Impact of feedback on adenoma detection rate: a systematic review and meta-analysis. *Ann Gastroenterol* 2021;34:214-23.
 302. Gurudu SR, Boroff ES, Crowell MD, et al. Impact of feedback on adenoma detection rates: outcomes of quality improvement program. *J Gastroenterol Hepatol* 2018;33:645-9.
 303. Inra JA, Nayor J, Rosenblatt M, et al. Comparison of colonoscopy quality measures across various practice settings and the impact of performance scorecards. *Dig Dis Sci* 2017;62:894-902.
 304. Kahi CJ, Ballard D, Shah AS, et al. Impact of a quarterly report card on colonoscopy quality measures. *Gastrointest Endosc* 2013;77:925-31.
 305. Zawaly K, Rumbolt C, Abou-Setta AM, et al. The efficacy of split-dose bowel preparations for polyp detection: a systematic review and meta-analysis. *Am J Gastroenterol* 2019;114:884-92.
 306. Desai M, Bilal M, Hamade N, et al. Increasing adenoma detection rates in the right side of the colon comparing retroflexion with a second forward view: a systematic review. *Gastrointest Endosc* 2019;89:453-9.
 307. Cohen J, Grunwald D, Grossberg LB, et al. The effect of right colon retroflexion on adenoma detection: a systematic review and meta-analysis. *J Clin Gastroenterol* 2017;51:818-24.
 308. Ngu WS, Bevan R, Tsiamoulos ZP, et al. Improved adenoma detection with Endocuff Vision: the ADENOMA randomised controlled trial. *Gut* 2019;68:280-8.
 309. Jacob A, Schafer A, Yong J, et al. Endocuff Vision-assisted colonoscopy: a randomized controlled trial. *Aust N Z J Surg* 2019;89:E174-8.
 310. Williet N, Tournier Q, Vernet C, et al. Effect of Endocuff-assisted colonoscopy on adenoma detection rate: meta-analysis of randomized controlled trials. *Endoscopy* 2018;50:846-60.
 311. Facciorusso A, Del Prete V, Buccino RV, et al. Comparative efficacy of colonoscope distal attachment devices in increasing rates of adenoma detection: a network meta-analysis. *Clin Gastroenterol Hepatol* 2018;16:1209-19.
 312. Leung FW, Koo M, Jia H, et al. Water exchange (WE) and quality improvement-enhanced advanced adenoma detection: a pooled data analysis of 6 randomized controlled trials. *J Clin Gastroenterol* 2020;54:212-7.
 313. Leung FW, Koo M, Cadoni S, et al. Water exchange produces significantly higher adenoma detection rate than water immersion: pooled data from 2 multisite randomized controlled trials. *J Clin Gastroenterol* 2019;53:204-9.
 314. Zhao SB, Wan H, Fu HY, et al. Quantitative assessment of the effect of position changes during colonoscopy withdrawal. *J Dig Dis* 2016;17:357-65.
 315. Waldmann E, Britto-Arias M, Gessl I, et al. Endoscopists with low adenoma detection rates benefit from high-definition endoscopy. *Surg Endosc* 2015;29:466-73.
 316. Kaminski MF, Anderson J, Valori R, et al. Leadership training to improve adenoma detection rate in screening colonoscopy: a randomised trial. *Gut* 2016;65:616-24.
 317. Evans B, Pace D, Borgaonkar M, et al. Effect of an educational intervention on colonoscopy quality outcomes. *Surg Endosc* 2020;34:5142-7.
 318. Wallace MB, Crook JE, Thomas CS, et al. Effect of an endoscopic quality improvement program on adenoma detection rates: a multicenter cluster-randomized controlled trial in a clinical practice setting (EQUIP-3). *Gastrointest Endosc* 2017;85:538-45.
 319. Ussui V, Coe S, Rizk C, et al. Stability of increased adenoma detection at colonoscopy. Follow-up of an endoscopic quality improvement program—EQUIP-II. *Am J Gastroenterol* 2015;110:489-96.
 320. Coe SG, Crook JE, Diehl NN, et al. An endoscopic quality improvement program improves detection of colorectal adenomas. *Am J Gastroenterol* 2013;108:219-26; quiz 227.
 321. Endoscopic Classification Review Group. Update on the Paris classification of superficial neoplastic lesions in the digestive tract. *Endoscopy* 2005;37:570-8.
 322. Tadepalli US, Feihel D, Miller KM, et al. A morphologic analysis of sessile serrated polyps observed during routine colonoscopy (with video). *Gastrointest Endosc* 2011;74:1360-8.
 323. Bond A, O'Toole P, Fisher G, et al. New-generation high-definition colonoscopes increase adenoma detection when screening a moderate-risk population for colorectal cancer. *Clin Colorectal Cancer* 2017;16:44-50.
 324. Zimmermann-Fraedrich K, Groth S, Sehner S, et al. Effects of two instrument-generation changes on adenoma detection rate during screening colonoscopy: results from a prospective randomized comparative study. *Endoscopy* 2018;50:878-85.
 325. Tziatzios G, Gkolfakis P, Lazaridis LD, et al. High-definition colonoscopy for improving adenoma detection: a systematic review and meta-analysis of randomized controlled studies. *Gastrointest Endosc* 2020;91:1027-36.
 326. Atkinson NSS, Ket S, Bassett P, et al. Narrow-band imaging for detection of neoplasia at colonoscopy: a meta-analysis of data from individual patients in randomized controlled trials. *Gastroenterology* 2019;157:462-71.
 327. Omata F, Ohde S, Deshpande GA, et al. Image-enhanced, chromo, and cap-assisted colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis. *Scand J Gastroenterol* 2014;49:222-37.
 328. Shu X, Wu G, Zhang Y, et al. Diagnostic value of linked color imaging based on endoscopy for gastric intestinal metaplasia: a systematic review and meta-analysis. *Ann Transl Med* 2021;9:506.
 329. Suzuki S, Aniwan S, Chiu HM, et al. Linked-color imaging detects more colorectal adenoma and serrated lesions: an international randomized controlled trial. *Clin Gastroenterol Hepatol* 2022;21:1493-502.

330. Pan H, Cai M, Liao Q, et al. Artificial intelligence-aid colonoscopy vs. conventional colonoscopy for polyp and adenoma detection: a systematic review of 7 discordant meta-analyses. *Front Med* 2021;8:775604.
331. Huang D, Shen J, Hong J, et al. Effect of artificial intelligence-aided colonoscopy for adenoma and polyp detection: a meta-analysis of randomized clinical trials. *Int J Colorectal Dis* 2022;37:495-506.
332. Mori Y, Wang P, Loberg M, et al. Impact of artificial intelligence on colonoscopy surveillance after polyp removal: a pooled analysis of randomized trials. *Clin Gastroenterol Hepatol* 2022;21:949-59.
333. Wallace MB, Sharma P, Bhandari P, et al. Impact of artificial intelligence on miss rate of colorectal neoplasia. *Gastroenterology* 2022;163:295-304.
334. Ladabaum U, Shepard J, Weng Y, et al. Computer-aided detection of polyps does not improve colonoscopist performance in a pragmatic implementation trial. *Gastroenterology* 2023;164:481-3.
335. Levy I, Bruckmayer L, Klang E, et al. Artificial intelligence-aided colonoscopy does not increase adenoma detection rate in routine clinical practice. *Am J Gastroenterol* 2022;117:1871-3.
336. Nehme F, Coronel E, Barringer DA, et al. Performance and attitudes toward real-time computer-aided polyp detection during colonoscopy in a large tertiary referral center in the United States. *Gastrointest Endosc* 2023;98:100-9.
337. Anderson JT. Assessments and skills improvement for endoscopists. *Best Pract Res Clin Gastroenterol* 2016;30:453-71.
338. Bowles CJ, Leicester R, Romaya C, et al. A prospective study of colonoscopy practice in the UK today: Are we adequately prepared for national colorectal cancer screening tomorrow? *Gut* 2004;53:277-83.
339. Lee TJ, Rutter MD, Blanks RG, et al. Colonoscopy quality measures: experience from the NHS Bowel Cancer Screening Programme. *Gut* 2012;61:1050-7.
340. Burr NE, Derbyshire E, Taylor J, et al. Variation in post-colonoscopy colorectal cancer across colonoscopy providers in English National Health Service: population based cohort study. *BMJ* 2019;367:l6090.
341. Bronzwaer MES, Depla A, van Lelyveld N, et al. Quality assurance of colonoscopy within the Dutch national colorectal cancer screening program. *Gastrointest Endosc* 2019;89:1-13.
342. Brenner H, Hoffmeister M, Brenner G, et al. Expected reduction of colorectal cancer incidence within 8 years after introduction of the German screening colonoscopy programme: estimates based on 1,875,708 screening colonoscopies. *Eur J Cancer* 2009;45:2027-33.
343. Gawron AJ, Yao Y, Gupta S, et al. Simplifying measurement of adenoma detection rates for colonoscopy. *Dig Dis Sci* 2021;66:3149-55.
344. Corley DA, Jensen CD, Lee JK, et al. Impact of a scalable training program on the quality of colonoscopy performance and risk of post-colonoscopy colorectal cancer. *Gastrointest Endosc* 2023;98:609-17.
345. Mazurek M, Murray A, Heitman SJ, et al. Association between endoscopist specialty and colonoscopy quality: a systematic review and meta-analysis. *Clin Gastroenterol Hepatol* 2021;20:1931-46.
346. Xu L, Zhang Y, Song H, et al. Nurse participation in colonoscopy observation versus the colonoscopist alone for polyp and adenoma detection: a meta-analysis of randomized, controlled trials. *Gastroenterol Res Pract* 2016;2016:7631981.